airmanbc的个人主页 - 老虎社区

airmanbc

airmanbc

暂无个人介绍

IP属地：未知

13关注

6粉丝

0主题

0勋章

2021-12-07

I like the word “undisputed” 💪

Tesla Stock Price Target Raised to $1,000 at UBS. Here Is Why.

2021-11-19

👍

Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading

2021-11-19

👍

Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older

2021-11-19

I just got my Moderna booster 💪

Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older

2021-10-26

right

Missed Tesla? Here's The Next $1 Trillion Company

2021-10-21

👍

FDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing

2021-10-15

👍

抱歉，原内容已删除

2021-08-23

we need this 🙏

抱歉，原内容已删除

2021-08-23

Well done Pfizer 👍

Pfizer and BioNTech SE shares surged in premarket trading

2021-08-13

Yes, we need a booster 👍

BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity

2021-08-12

This is good news 👍

Toplines Before US Market Open on Thursday

2021-08-06

👍

抱歉，原内容已删除

2021-08-05

💪

Roku Slides as Reopening Leads to Less Streaming Viewing

2021-08-05

Can I still buy Moderna?

抱歉，原内容已删除

2021-08-04

We need more factories 👍

Tech Companies Are Facing a Global Chip Shortage: 5 Tips for Investors

2021-08-04

We need this 👍

AMD gained over 5% and reached record high

2021-08-04

Great news from Pfizer 👏🏻 well done

抱歉，原内容已删除

2021-08-04

That’s good

3 COVID Stocks That Could Soar Higher

2021-08-02

I am watching 😳

When Will Stocks Drop? Watch Profit Margins (and Get Nervous)

2021-08-02

Hurray 🎉

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3582662259235370","uuid":"3582662259235370","gmtCreate":1619568264754,"gmtModify":1706620618437,"name":"airmanbc","pinyin":"airmanbc","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":13,"tweetSize":67,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.22%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":606265454,"gmtCreate":1638886915646,"gmtModify":1638886923118,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"I like the word “undisputed” 💪","listText":"I like the word “undisputed” 💪","text":"I like the word “undisputed” 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606265454","repostId":"1195364731","repostType":4,"repost":{"id":"1195364731","pubTimestamp":1638885960,"share":"https://www.laohu8.com/m/news/1195364731?lang=&edition=full","pubTime":"2021-12-07 22:06","market":"us","language":"en","title":"Tesla Stock Price Target Raised to $1,000 at UBS. Here Is Why.","url":"https://stock-news.laohu8.com/highlight/detail?id=1195364731","media":"Barrons","summary":"Shares of Tesla were rebounding Tuesday after UBS raised its price target on the stock, calling the ","content":"<p>Shares of&nbsp;Tesla&nbsp;were rebounding Tuesday after UBS raised its price target on the stock, calling the electric-vehicle company the “undisputed leader” in the market.</p>\n<p>Analyst Patrick Hummel increased his price target to $1,000 from $725, saying global demand for electric vehicles will propel the company to continue beating expectations in 2022. Hummel maintained a Neutral rating on the stock.</p>\n<p>The electric-vehicle manufacturer had a rough Monday, with the stock closing at $1,009.01, slipping dangerously close to its third bear market of the year. Tesla (ticker:TSLA) was faring better Tuesday, with shares rising 3.7% to $1,046 in premarket trading.</p>\n<p>Of the 41 analysts surveyed by FactSet, 17 rate the stock at Buy or Overweight, 12 rate it a Hold, and 12 rate it a Sell. The average price target is $851.09.</p>\n<p>Tesla’s access to chips and batteries through vertical integration sets it apart from its competitors, helping the company cement market leadership with about 20% global EV share, the analyst said.</p>\n<p>“We’ve raised estimates sharply to reflect this undisputed leadership, however, current valuation fully reflects such steep curve,” Hummel wrote in a research note Tuesday.</p>\n<p>The title of Hummel’s research note on Tesla was: “Cementing leadership as EV market takes off: New $1,000 price target (from $725) – no rival to get even close to Tesla in 2022.”</p>\n<p>Hummel is forecasting Tesla’s car sales to grow from 894,000 in 2021 to 1.4 million in 2022, and reach 2.9 million by 2025, more than competitors&nbsp;BMW&nbsp;(BMW.DE) or&nbsp;Mercedes-Benz.He expects EVs in general to account for 50% of global car sales by 2030.</p>\n<p>A big part of Tesla’s advantage is the software’s scalability, which can drive a big revenue pool with even higher margins well beyond 2025, Hummel said.</p>\n<p>“Software is the next battleground in the global car industry, and no other carmaker is closer to monetize fully autonomous driving for everyday use, and the scalability of Tesla’s technology creates the biggest software-driven revenue opportunity in the industry,” he wrote.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock Price Target Raised to $1,000 at UBS. Here Is Why.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock Price Target Raised to $1,000 at UBS. Here Is Why.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-tsla-stock-price-target-raised-ubs-electric-vehicles-51638885474?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Tesla were rebounding Tuesday after UBS raised its price target on the stock, calling the electric-vehicle company the “undisputed leader” in the market.\nAnalyst Patrick Hummel increased his...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-tsla-stock-price-target-raised-ubs-electric-vehicles-51638885474?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-tsla-stock-price-target-raised-ubs-electric-vehicles-51638885474?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195364731","content_text":"Shares of Tesla were rebounding Tuesday after UBS raised its price target on the stock, calling the electric-vehicle company the “undisputed leader” in the market.\nAnalyst Patrick Hummel increased his price target to $1,000 from $725, saying global demand for electric vehicles will propel the company to continue beating expectations in 2022. Hummel maintained a Neutral rating on the stock.\nThe electric-vehicle manufacturer had a rough Monday, with the stock closing at $1,009.01, slipping dangerously close to its third bear market of the year. Tesla (ticker:TSLA) was faring better Tuesday, with shares rising 3.7% to $1,046 in premarket trading.\nOf the 41 analysts surveyed by FactSet, 17 rate the stock at Buy or Overweight, 12 rate it a Hold, and 12 rate it a Sell. The average price target is $851.09.\nTesla’s access to chips and batteries through vertical integration sets it apart from its competitors, helping the company cement market leadership with about 20% global EV share, the analyst said.\n“We’ve raised estimates sharply to reflect this undisputed leadership, however, current valuation fully reflects such steep curve,” Hummel wrote in a research note Tuesday.\nThe title of Hummel’s research note on Tesla was: “Cementing leadership as EV market takes off: New $1,000 price target (from $725) – no rival to get even close to Tesla in 2022.”\nHummel is forecasting Tesla’s car sales to grow from 894,000 in 2021 to 1.4 million in 2022, and reach 2.9 million by 2025, more than competitors BMW (BMW.DE) or Mercedes-Benz.He expects EVs in general to account for 50% of global car sales by 2030.\nA big part of Tesla’s advantage is the software’s scalability, which can drive a big revenue pool with even higher margins well beyond 2025, Hummel said.\n“Software is the next battleground in the global car industry, and no other carmaker is closer to monetize fully autonomous driving for everyday use, and the scalability of Tesla’s technology creates the biggest software-driven revenue opportunity in the industry,” he wrote.","news_type":1},"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876567162,"gmtCreate":1637333054328,"gmtModify":1637333058832,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876567162","repostId":"1129693973","repostType":2,"repost":{"id":"1129693973","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637332940,"share":"https://www.laohu8.com/m/news/1129693973?lang=&edition=full","pubTime":"2021-11-19 22:42","market":"us","language":"en","title":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1129693973","media":"Tiger Newspress","summary":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US)","content":"<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p>\n<p>The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p>\n<p>Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p>\n<p>The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p>\n<p>Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129693973","content_text":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.\nThe report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"\nMoreover，Moderna, Inc. today announced that the U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":386,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876274245,"gmtCreate":1637327616774,"gmtModify":1637327616950,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876274245","repostId":"1138047553","repostType":4,"repost":{"id":"1138047553","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1},"isVote":1,"tweetType":1,"viewCount":712,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876274192,"gmtCreate":1637327527189,"gmtModify":1637327527331,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"I just got my Moderna booster 💪","listText":"I just got my Moderna booster 💪","text":"I just got my Moderna booster 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876274192","repostId":"1138047553","repostType":2,"repost":{"id":"1138047553","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1},"isVote":1,"tweetType":1,"viewCount":708,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852888572,"gmtCreate":1635257254747,"gmtModify":1635257319078,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"right&nbsp;","listText":"right&nbsp;","text":"right","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852888572","repostId":"2178721405","repostType":4,"repost":{"id":"2178721405","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1635252117,"share":"https://www.laohu8.com/m/news/2178721405?lang=&edition=full","pubTime":"2021-10-26 20:41","market":"us","language":"en","title":"Missed Tesla? Here's The Next $1 Trillion Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2178721405","media":"Investors","summary":"The idea of an S&P 500 company hitting $1 trillion in market value used to seem impossible. But analysts insist another is on the way.","content":"<p>The idea of an S&amp;P 500 company hitting $1 trillion in market value used to seem impossible. But <b>Tesla</b> just did it — and analysts insist another is on the way.</p>\n<p>Analysts think <b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> should be the sixth S&amp;P 500 company valued at $1 trillion or more in 12 months or less, returning it to the trillion-dollar club. It would put the social networking giant in the same trillion-dollar league as <b>Apple</b>, <b>Microsoft</b>, <b>Alphabet</b>, <b>Amazon.com</b> and now Tesla.</p>\n<p>Shares of Facebook closed Monday at 328.69, down more than 14% from the 52-week high. That parked the company's valuation at $927 billion. But that was prior to the company late Monday topping third-quarter profit forecasts by 1.3% and jumping in after-hours trading to north of 337 a share. At this price, Facebook is worth $950 billion.</p>\n<p>It's only a matter of time until Facebook returns to the rarefied trillion-dollar air, though, say S&amp;P 500 analysts.</p>\n<h2>Trillion Dollar Redux For Facebook</h2>\n<p>Predicting Facebook will be a $1 trillion company is somewhat of an anticlimactic call.</p>\n<p>The company first closed above a trillion-dollar valuation back in July of this year. But since then, it's been on a rough run. Allegations of putting profit ahead of users' mental health, a high-profile outage and exposure to data limits at Apple knocked Facebook from its trillion-dollar perch. <b>Snap</b>'s recent disappointing third quarter and warning of problems tailoring social media ads on iPhones only fanned the worries.</p>\n<p>But analysts remain resolute on Facebook's future. They're calling for the stock to rally another 27% from Monday's close to 416.43 in 12 months, says data from S&amp;P Global Market Intelligence and MarketSmith. And if they're right, that would make Facebook a company valued at $1.17 billion. Should you buy Facebook stock now?</p>\n<p>Interestingly, if analysts are right, Facebook would supplant Tesla as the fifth most-valuable company in the S&amp;P 500. Analysts actually think Tesla's stock will drop 23% to 787.15. And if that's correct, it means Tesla would be worth just $779.3 billion, or a third less than what they think Facebook will be worth in 12 months. Should you buy Tesla stock now?</p>\n<h2>Who's Up In S&amp;P 500 After Facebook?</h2>\n<p>Facebook and Tesla might jockey for the trillion-dollar prize. But other than those two, are any other S&amp;P 500 stocks anywhere near a trillion? Nothing immediate.</p>\n<p>Warren Buffett's <b>Berkshire Hathaway</b> would appear next in line, as its market value is now $657.9 billion. Analysts, though, think even in 12 months time the company will be worth just $730.8 billion, falling shy of the trillion-dollar mark by nearly 40%. Also, it's not a particularly fast grower, so unlikely to surprise much to the upside. Analysts think Berkshire Hathaway's adjusted profit per share will only grow by 6.9% in 2022.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a></b> is a likely candidate in due time. The payment processing firm is already worth nearly $500 billion. And its adjusted profit per share is seen jumping 25% in 2022 to $7.26. Even so, analysts don't think it's going to happen anytime soon. Analysts are calling for the stock to inch up just 0.9% in 12 months.</p>\n<p>So it seems the world might need to be satisfied with five, or maybe six, trillion dollar companies for some time.</p>\n<h2>Analysts: The Most Valuable S&amp;P 500 Companies In The Future</h2>\n<p><i>Current and projected market values</i></p>\n<table>\n <thead>\n  <tr>\n   <th>Company</th>\n   <th>Ticker</th>\n   <th>Stock YTD % ch.</th>\n   <th>Market value now ($ trillions)</th>\n   <th>Analysts' 12-month market value target</th>\n   <th>Sector</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>Apple</td>\n   <td></td>\n   <td>12.0%</td>\n   <td>$2.5</td>\n   <td><b>$2.7</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Microsoft</td>\n   <td></td>\n   <td>38.5%</td>\n   <td>$2.3</td>\n   <td><b>$2.5</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Alphabet</td>\n   <td></td>\n   <td>56.8%</td>\n   <td>$1.8</td>\n   <td><b>$2.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Amazon.com</td>\n   <td></td>\n   <td>1.9%</td>\n   <td>$1.7</td>\n   <td><b>$2.1</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Facebook</td>\n   <td></td>\n   <td>20.3%</td>\n   <td>$0.9</td>\n   <td><b>$1.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Tesla</td>\n   <td></td>\n   <td>45.2%</td>\n   <td>$1.0</td>\n   <td><b>$0.8</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Berkshire Hathaway</td>\n   <td></td>\n   <td>25.5%</td>\n   <td>$0.7</td>\n   <td><b>$0.7</b></td>\n   <td>Financials</td>\n  </tr>\n  <tr>\n   <td>Visa</td>\n   <td></td>\n   <td>6.9%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Nvidia</td>\n   <td></td>\n   <td>77.4%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>JPMorgan Chase</td>\n   <td></td>\n   <td>34.5%</td>\n   <td>$0.5</td>\n   <td><b>$0.5</b></td>\n   <td>Financials</td>\n  </tr>\n </tbody>\n</table>\n<h5>Sources: IBD, S&amp;P Global Market Intelligence</h5>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Missed Tesla? Here's The Next $1 Trillion Company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMissed Tesla? Here's The Next $1 Trillion Company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-10-26 20:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>The idea of an S&amp;P 500 company hitting $1 trillion in market value used to seem impossible. But <b>Tesla</b> just did it — and analysts insist another is on the way.</p>\n<p>Analysts think <b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> should be the sixth S&amp;P 500 company valued at $1 trillion or more in 12 months or less, returning it to the trillion-dollar club. It would put the social networking giant in the same trillion-dollar league as <b>Apple</b>, <b>Microsoft</b>, <b>Alphabet</b>, <b>Amazon.com</b> and now Tesla.</p>\n<p>Shares of Facebook closed Monday at 328.69, down more than 14% from the 52-week high. That parked the company's valuation at $927 billion. But that was prior to the company late Monday topping third-quarter profit forecasts by 1.3% and jumping in after-hours trading to north of 337 a share. At this price, Facebook is worth $950 billion.</p>\n<p>It's only a matter of time until Facebook returns to the rarefied trillion-dollar air, though, say S&amp;P 500 analysts.</p>\n<h2>Trillion Dollar Redux For Facebook</h2>\n<p>Predicting Facebook will be a $1 trillion company is somewhat of an anticlimactic call.</p>\n<p>The company first closed above a trillion-dollar valuation back in July of this year. But since then, it's been on a rough run. Allegations of putting profit ahead of users' mental health, a high-profile outage and exposure to data limits at Apple knocked Facebook from its trillion-dollar perch. <b>Snap</b>'s recent disappointing third quarter and warning of problems tailoring social media ads on iPhones only fanned the worries.</p>\n<p>But analysts remain resolute on Facebook's future. They're calling for the stock to rally another 27% from Monday's close to 416.43 in 12 months, says data from S&amp;P Global Market Intelligence and MarketSmith. And if they're right, that would make Facebook a company valued at $1.17 billion. Should you buy Facebook stock now?</p>\n<p>Interestingly, if analysts are right, Facebook would supplant Tesla as the fifth most-valuable company in the S&amp;P 500. Analysts actually think Tesla's stock will drop 23% to 787.15. And if that's correct, it means Tesla would be worth just $779.3 billion, or a third less than what they think Facebook will be worth in 12 months. Should you buy Tesla stock now?</p>\n<h2>Who's Up In S&amp;P 500 After Facebook?</h2>\n<p>Facebook and Tesla might jockey for the trillion-dollar prize. But other than those two, are any other S&amp;P 500 stocks anywhere near a trillion? Nothing immediate.</p>\n<p>Warren Buffett's <b>Berkshire Hathaway</b> would appear next in line, as its market value is now $657.9 billion. Analysts, though, think even in 12 months time the company will be worth just $730.8 billion, falling shy of the trillion-dollar mark by nearly 40%. Also, it's not a particularly fast grower, so unlikely to surprise much to the upside. Analysts think Berkshire Hathaway's adjusted profit per share will only grow by 6.9% in 2022.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a></b> is a likely candidate in due time. The payment processing firm is already worth nearly $500 billion. And its adjusted profit per share is seen jumping 25% in 2022 to $7.26. Even so, analysts don't think it's going to happen anytime soon. Analysts are calling for the stock to inch up just 0.9% in 12 months.</p>\n<p>So it seems the world might need to be satisfied with five, or maybe six, trillion dollar companies for some time.</p>\n<h2>Analysts: The Most Valuable S&amp;P 500 Companies In The Future</h2>\n<p><i>Current and projected market values</i></p>\n<table>\n <thead>\n  <tr>\n   <th>Company</th>\n   <th>Ticker</th>\n   <th>Stock YTD % ch.</th>\n   <th>Market value now ($ trillions)</th>\n   <th>Analysts' 12-month market value target</th>\n   <th>Sector</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>Apple</td>\n   <td></td>\n   <td>12.0%</td>\n   <td>$2.5</td>\n   <td><b>$2.7</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Microsoft</td>\n   <td></td>\n   <td>38.5%</td>\n   <td>$2.3</td>\n   <td><b>$2.5</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Alphabet</td>\n   <td></td>\n   <td>56.8%</td>\n   <td>$1.8</td>\n   <td><b>$2.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Amazon.com</td>\n   <td></td>\n   <td>1.9%</td>\n   <td>$1.7</td>\n   <td><b>$2.1</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Facebook</td>\n   <td></td>\n   <td>20.3%</td>\n   <td>$0.9</td>\n   <td><b>$1.2</b></td>\n   <td>Communication Services</td>\n  </tr>\n  <tr>\n   <td>Tesla</td>\n   <td></td>\n   <td>45.2%</td>\n   <td>$1.0</td>\n   <td><b>$0.8</b></td>\n   <td>Consumer Discretionary</td>\n  </tr>\n  <tr>\n   <td>Berkshire Hathaway</td>\n   <td></td>\n   <td>25.5%</td>\n   <td>$0.7</td>\n   <td><b>$0.7</b></td>\n   <td>Financials</td>\n  </tr>\n  <tr>\n   <td>Visa</td>\n   <td></td>\n   <td>6.9%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>Nvidia</td>\n   <td></td>\n   <td>77.4%</td>\n   <td>$0.6</td>\n   <td><b>$0.6</b></td>\n   <td>Information Technology</td>\n  </tr>\n  <tr>\n   <td>JPMorgan Chase</td>\n   <td></td>\n   <td>34.5%</td>\n   <td>$0.5</td>\n   <td><b>$0.5</b></td>\n   <td>Financials</td>\n  </tr>\n </tbody>\n</table>\n<h5>Sources: IBD, S&amp;P Global Market Intelligence</h5>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","BRK.A":"伯克希尔",".SPX":"S&P 500 Index","BRK.B":"伯克希尔B","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178721405","content_text":"The idea of an S&P 500 company hitting $1 trillion in market value used to seem impossible. But Tesla just did it — and analysts insist another is on the way.\nAnalysts think Facebook should be the sixth S&P 500 company valued at $1 trillion or more in 12 months or less, returning it to the trillion-dollar club. It would put the social networking giant in the same trillion-dollar league as Apple, Microsoft, Alphabet, Amazon.com and now Tesla.\nShares of Facebook closed Monday at 328.69, down more than 14% from the 52-week high. That parked the company's valuation at $927 billion. But that was prior to the company late Monday topping third-quarter profit forecasts by 1.3% and jumping in after-hours trading to north of 337 a share. At this price, Facebook is worth $950 billion.\nIt's only a matter of time until Facebook returns to the rarefied trillion-dollar air, though, say S&P 500 analysts.\nTrillion Dollar Redux For Facebook\nPredicting Facebook will be a $1 trillion company is somewhat of an anticlimactic call.\nThe company first closed above a trillion-dollar valuation back in July of this year. But since then, it's been on a rough run. Allegations of putting profit ahead of users' mental health, a high-profile outage and exposure to data limits at Apple knocked Facebook from its trillion-dollar perch. Snap's recent disappointing third quarter and warning of problems tailoring social media ads on iPhones only fanned the worries.\nBut analysts remain resolute on Facebook's future. They're calling for the stock to rally another 27% from Monday's close to 416.43 in 12 months, says data from S&P Global Market Intelligence and MarketSmith. And if they're right, that would make Facebook a company valued at $1.17 billion. Should you buy Facebook stock now?\nInterestingly, if analysts are right, Facebook would supplant Tesla as the fifth most-valuable company in the S&P 500. Analysts actually think Tesla's stock will drop 23% to 787.15. And if that's correct, it means Tesla would be worth just $779.3 billion, or a third less than what they think Facebook will be worth in 12 months. Should you buy Tesla stock now?\nWho's Up In S&P 500 After Facebook?\nFacebook and Tesla might jockey for the trillion-dollar prize. But other than those two, are any other S&P 500 stocks anywhere near a trillion? Nothing immediate.\nWarren Buffett's Berkshire Hathaway would appear next in line, as its market value is now $657.9 billion. Analysts, though, think even in 12 months time the company will be worth just $730.8 billion, falling shy of the trillion-dollar mark by nearly 40%. Also, it's not a particularly fast grower, so unlikely to surprise much to the upside. Analysts think Berkshire Hathaway's adjusted profit per share will only grow by 6.9% in 2022.\nVisa is a likely candidate in due time. The payment processing firm is already worth nearly $500 billion. And its adjusted profit per share is seen jumping 25% in 2022 to $7.26. Even so, analysts don't think it's going to happen anytime soon. Analysts are calling for the stock to inch up just 0.9% in 12 months.\nSo it seems the world might need to be satisfied with five, or maybe six, trillion dollar companies for some time.\nAnalysts: The Most Valuable S&P 500 Companies In The Future\nCurrent and projected market values\n\n\n\nCompany\nTicker\nStock YTD % ch.\nMarket value now ($ trillions)\nAnalysts' 12-month market value target\nSector\n\n\n\n\nApple\n\n12.0%\n$2.5\n$2.7\nInformation Technology\n\n\nMicrosoft\n\n38.5%\n$2.3\n$2.5\nInformation Technology\n\n\nAlphabet\n\n56.8%\n$1.8\n$2.2\nCommunication Services\n\n\nAmazon.com\n\n1.9%\n$1.7\n$2.1\nConsumer Discretionary\n\n\nFacebook\n\n20.3%\n$0.9\n$1.2\nCommunication Services\n\n\nTesla\n\n45.2%\n$1.0\n$0.8\nConsumer Discretionary\n\n\nBerkshire Hathaway\n\n25.5%\n$0.7\n$0.7\nFinancials\n\n\nVisa\n\n6.9%\n$0.6\n$0.6\nInformation Technology\n\n\nNvidia\n\n77.4%\n$0.6\n$0.6\nInformation Technology\n\n\nJPMorgan Chase\n\n34.5%\n$0.5\n$0.5\nFinancials\n\n\n\nSources: IBD, S&P Global Market Intelligence","news_type":1},"isVote":1,"tweetType":1,"viewCount":654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853879081,"gmtCreate":1634793211465,"gmtModify":1634793211614,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853879081","repostId":"1115514997","repostType":4,"repost":{"id":"1115514997","pubTimestamp":1634771335,"share":"https://www.laohu8.com/m/news/1115514997?lang=&edition=full","pubTime":"2021-10-21 07:08","market":"us","language":"en","title":"FDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing","url":"https://stock-news.laohu8.com/highlight/detail?id=1115514997","media":"Bloomberg","summary":"Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be gi","content":"<ul>\n <li>Actions mean extra doses now allowed for all three U.S. shots</li>\n <li>Agency allows different shots to be given to bolster immunity</li>\n</ul>\n<p>The U.S. Food and Drug Administration cleared a path for millions more Americans to receive Covid-19 vaccine booster shots, as the nation looks to bolster its defenses and prevent another virus surge.</p>\n<p>The agency said in a&nbsp;statement&nbsp;on Wednesday that&nbsp;Moderna Inc.&nbsp;vaccine recipients 65 and over can receive a third shot, as can adults 18 and up who are at high risk of severe Covid or with frequent institutional or occupational exposure to the virus that causes the disease.</p>\n<p>Additionally, all J&amp;J recipients 18 and older are eligible for a booster shot at least two months after receiving their first dose.</p>\n<p>The agency also allowed each of the available Covid vaccines to be used as a booster dose for eligible individuals following completion of a primary vaccination with a different vaccine.</p>\n<p>The moves will mean the U.S. has a bigger toolkit to try to limit a potential winter virus rebound. The summer’s delta-variant fueled spike in infections helped increase urgency to make boosters available, and health officials across the U.S. are eager to forestall a rebound in cases that could cripple hospitals and disrupt work and school this winter.</p>\n<p>FDA officials indicated they would also move quickly to expand eligibility for booster shots as more data become available or if breakthrough cases start to rise in younger adults.</p>\n<p>“We will not hesitate to drop this age range as we see that that benefit clearly outweighs the risk,” said Peter Marks, the head of the agency’s Center for Biologics Evaluation and Research, during a media briefing following the announcement.</p>\n<p>The clearances came after a panel of expert advisers to the FDA unanimously backed the Moderna and J&amp;J booster regimens in two days of meetings last week. Regulators have now signed off on boosters for all three coronavirus vaccines available in the U.S.</p>\n<p>Last month, the FDA said people 65 and over and others who are at heightened risk of severe Covid were eligible for a booster dose of the vaccine developed by&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE.</p>\n<p>Moderna shares climbed 1% in after-hours trading in New York, while J&amp;J shares gained 0.4% and Pfizer shares rose 0.2%. U.S.-traded shares of Germany-based BioNTech gained 0.9%.</p>\n<p><b>Smaller Dose</b></p>\n<p>The Moderna booster shot authorized by the FDA is half the dose that is given in the initial two-shot series, and it should be given at least six months after the initial inoculation, regulators said.</p>\n<p>The FDA said that a single booster dose of the Pfizer vaccine may be given at least 6 months after completing the primary series to people 18 to 64 with frequent institutional or occupational exposure to the coronavirus.</p>\n<p>In permitting mixing and matching, the FDA is allowing J&amp;J vaccine recipients to receive an additional dose of any cleared vaccine after two months. Likewise, recipients of Moderna and Pfizer who are eligible for a booster would receive their booster, including J&amp;J’s shot, at least six months after their initial immunization regimen.</p>\n<p>Marks said during the call with reporters that different combinations produce different antibody levels in the short term, but it isn’t clear what that means in terms of actual long-term protection.</p>\n<p>Seen as a convenient, effective alternative to two-shot messenger RNA vaccines, J&amp;J’s single-shot immunization has seen far less use in the U.S., in part because it isn’t as effective. The drugmaker has also experienced manufacturing problems that limited the shot’s distribution.</p>\n<p>The decision to allow mixing will create greater flexibility and is beneficial to global public health, Paul Stoffels, J&amp;J’s chief scientific officer, said in a statement.</p>\n<p>Before the Moderna and J&amp;J booster shots can be administered, the Centers for Disease Control and Prevention’s Advisory Panel on Immunization Practices will make further recommendations about who should receive them. The panel is scheduled to discuss boosters on Thursday.</p>\n<p>The next big milestone for the U.S. immunization effort looms next week, when the FDA advisory panel is expected to weigh Pfizer’s proposed Covid vaccine for children ages 5 to 11. If authorized, it could begin to roll out to pediatricians’ offices and drugstores as soon as next month.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-21 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be given to bolster immunity\n\nThe U.S. Food and Drug Administration cleared a path for millions more ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","MRK":"默沙东","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","JNJ":"强生","BNTX":"BioNTech SE"},"source_url":"https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115514997","content_text":"Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be given to bolster immunity\n\nThe U.S. Food and Drug Administration cleared a path for millions more Americans to receive Covid-19 vaccine booster shots, as the nation looks to bolster its defenses and prevent another virus surge.\nThe agency said in a statement on Wednesday that Moderna Inc. vaccine recipients 65 and over can receive a third shot, as can adults 18 and up who are at high risk of severe Covid or with frequent institutional or occupational exposure to the virus that causes the disease.\nAdditionally, all J&J recipients 18 and older are eligible for a booster shot at least two months after receiving their first dose.\nThe agency also allowed each of the available Covid vaccines to be used as a booster dose for eligible individuals following completion of a primary vaccination with a different vaccine.\nThe moves will mean the U.S. has a bigger toolkit to try to limit a potential winter virus rebound. The summer’s delta-variant fueled spike in infections helped increase urgency to make boosters available, and health officials across the U.S. are eager to forestall a rebound in cases that could cripple hospitals and disrupt work and school this winter.\nFDA officials indicated they would also move quickly to expand eligibility for booster shots as more data become available or if breakthrough cases start to rise in younger adults.\n“We will not hesitate to drop this age range as we see that that benefit clearly outweighs the risk,” said Peter Marks, the head of the agency’s Center for Biologics Evaluation and Research, during a media briefing following the announcement.\nThe clearances came after a panel of expert advisers to the FDA unanimously backed the Moderna and J&J booster regimens in two days of meetings last week. Regulators have now signed off on boosters for all three coronavirus vaccines available in the U.S.\nLast month, the FDA said people 65 and over and others who are at heightened risk of severe Covid were eligible for a booster dose of the vaccine developed by Pfizer Inc. and BioNTech SE.\nModerna shares climbed 1% in after-hours trading in New York, while J&J shares gained 0.4% and Pfizer shares rose 0.2%. U.S.-traded shares of Germany-based BioNTech gained 0.9%.\nSmaller Dose\nThe Moderna booster shot authorized by the FDA is half the dose that is given in the initial two-shot series, and it should be given at least six months after the initial inoculation, regulators said.\nThe FDA said that a single booster dose of the Pfizer vaccine may be given at least 6 months after completing the primary series to people 18 to 64 with frequent institutional or occupational exposure to the coronavirus.\nIn permitting mixing and matching, the FDA is allowing J&J vaccine recipients to receive an additional dose of any cleared vaccine after two months. Likewise, recipients of Moderna and Pfizer who are eligible for a booster would receive their booster, including J&J’s shot, at least six months after their initial immunization regimen.\nMarks said during the call with reporters that different combinations produce different antibody levels in the short term, but it isn’t clear what that means in terms of actual long-term protection.\nSeen as a convenient, effective alternative to two-shot messenger RNA vaccines, J&J’s single-shot immunization has seen far less use in the U.S., in part because it isn’t as effective. The drugmaker has also experienced manufacturing problems that limited the shot’s distribution.\nThe decision to allow mixing will create greater flexibility and is beneficial to global public health, Paul Stoffels, J&J’s chief scientific officer, said in a statement.\nBefore the Moderna and J&J booster shots can be administered, the Centers for Disease Control and Prevention’s Advisory Panel on Immunization Practices will make further recommendations about who should receive them. The panel is scheduled to discuss boosters on Thursday.\nThe next big milestone for the U.S. immunization effort looms next week, when the FDA advisory panel is expected to weigh Pfizer’s proposed Covid vaccine for children ages 5 to 11. If authorized, it could begin to roll out to pediatricians’ offices and drugstores as soon as next month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":544,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824668787,"gmtCreate":1634308679503,"gmtModify":1634308679653,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/824668787","repostId":"2175143354","repostType":2,"isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":835534807,"gmtCreate":1629726519709,"gmtModify":1631889829164,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"we need this 🙏","listText":"we need this 🙏","text":"we need this 🙏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/835534807","repostId":"1189910879","repostType":4,"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835846530,"gmtCreate":1629706882520,"gmtModify":1631884085491,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Well done Pfizer 👍","listText":"Well done Pfizer 👍","text":"Well done Pfizer 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835846530","repostId":"1104804215","repostType":4,"repost":{"id":"1104804215","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629706373,"share":"https://www.laohu8.com/m/news/1104804215?lang=&edition=full","pubTime":"2021-08-23 16:12","market":"us","language":"en","title":"Pfizer and BioNTech SE shares surged in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104804215","media":"Tiger Newspress","summary":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval","content":"<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p>\n<p><img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p>\n<p>The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p>\n<p>Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p>\n<p>An F.D.A. spokeswoman declined to comment.</p>\n<p>The agency had recently set an unofficial deadline for approval of around Labor Day.</p>\n<p>The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p>\n<p>Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p>\n<p>Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p>\n<p>The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p>\n<p>Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech SE shares surged in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech SE shares surged in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-23 16:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p>\n<p><img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p>\n<p>The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p>\n<p>Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p>\n<p>An F.D.A. spokeswoman declined to comment.</p>\n<p>The agency had recently set an unofficial deadline for approval of around Labor Day.</p>\n<p>The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p>\n<p>Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p>\n<p>Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p>\n<p>The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p>\n<p>Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104804215","content_text":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.\n\nThe Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.\nRegulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.\nAn F.D.A. spokeswoman declined to comment.\nThe agency had recently set an unofficial deadline for approval of around Labor Day.\nThe approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.\nSome universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month said it planned to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.\nOnce it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.\nThe F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.\nRegulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.","news_type":1},"isVote":1,"tweetType":1,"viewCount":63,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897937226,"gmtCreate":1628867386165,"gmtModify":1631889829168,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Yes, we need a booster 👍","listText":"Yes, we need a booster 👍","text":"Yes, we need a booster 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/897937226","repostId":"1141206470","repostType":4,"repost":{"id":"1141206470","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628861824,"share":"https://www.laohu8.com/m/news/1141206470?lang=&edition=full","pubTime":"2021-08-13 21:37","market":"us","language":"en","title":"BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1141206470","media":"Tiger Newspress","summary":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster ","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141206470","content_text":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.\nBioNTech was up 3% and Moderna gained 3%, while Pfizer , which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.\n\nLate on Thursday, the U.S. Food and Drug Administration authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.\nPfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.\nGoing forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.","news_type":1},"isVote":1,"tweetType":1,"viewCount":197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895798931,"gmtCreate":1628771569923,"gmtModify":1631889829170,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"This is good news 👍","listText":"This is good news 👍","text":"This is good news 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/895798931","repostId":"1119893366","repostType":4,"repost":{"id":"1119893366","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628770120,"share":"https://www.laohu8.com/m/news/1119893366?lang=&edition=full","pubTime":"2021-08-12 20:08","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1119893366","media":"Tiger Newspress","summary":"Futures tracking the Dow hit a record high on Thursday ahead of earnings reports from companies incl","content":"<p>Futures tracking the Dow hit a record high on Thursday ahead of earnings reports from companies including Walt Disney and data expected to show a jobs market recovery was on track.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were up 35 points, or 0.1%, S&amp;P 500 E-minis were up 2 points, or 0.05% and Nasdaq 100 E-minis were up 8.5 points, or 0.06%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f35f9eb8d6574ed6eb40236f67b99935\" tg-width=\"579\" tg-height=\"200\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>Rate-sensitive lenders JPMorgan Chase &amp; Co, Wells Fargo &amp; Co, Bank of America Corp and Goldman Sachs Group Inc edged higher before the opening bell.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> – The software platform company matched Wall Street forecasts with adjusted quarterly earnings of 4 cents per share and revenue beating analyst forecasts. Sales rose 49% from a year ago, and the stock rallied 5.7% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/CYBR\">CyberArk</a> – The cybersecurity company earned an adjusted 1 cent per share for its latest quarter, compared with a consensus estimate of 2 cents, while revenue came in above estimates with subscription revenue more than doubling from a year ago. CyberArk shares slid 4.9% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/UTZ\">Utz Brands, Inc.</a> – The snack maker’s stock fell 4.5% in the premarket after it missed estimates by 2 cents with adjusted quarterly earnings of 13 cents per share, although revenue did beat Wall Street forecasts. Utz expects continued strong demand for its products, but also expects costs to remain elevated for the remainder of the year.</p>\n<p><a href=\"https://laohu8.com/S/EBAY\">eBay</a> – eBay beat estimates by 4 cents with adjusted quarterly earnings of 99 cents per share. However, it reported a decline in active buyers and is forecasting lower than expected revenue for the current quarter as overall e-commerce trends soften. eBay fell 1.5% in premarket action.</p>\n<p><a href=\"https://laohu8.com/S/BMBL\">Bumble Inc.</a> – Bumble lost 6 cents per share for its latest quarter, compared with consensus estimates for a 1 cent per-share profit. However, the dating service operator’s revenue topped forecasts as its paying user numbers jumped 20% from a year earlier, and it issued upbeat current-quarter revenue guidance. Bumble gained 1.7% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/SONO\">Sonos Inc</a> – Sonos surged 11.6% in premarket trading after it reported a surprise profit of 12 cents per share, with analysts having expected a quarterly loss of 17 cents per share. The maker of home audio equipment also issued strong current-quarter and full-year sales guidance.</p>\n<p><a href=\"https://laohu8.com/S/OPEN\">Opendoor Technologies Inc</a> – Opendoor soared 19.5% in premarket action after reporting it lost 24 cents per share for its latest quarter, 10 cents less than analysts had been projecting. The home buying and selling company also reported better-than-expected revenue, in addition to issuing an upbeat current-quarter sales forecast.</p>\n<p><a href=\"https://laohu8.com/S/RIDE\">Lordstown Motors Corp.</a> – Lordstown Motors is seeing its shares rally in the premarket after saying it was on track to begin limited production of its Endurance electric pickup truck by the end of September. Lordstown gained 1.6% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/DASH\">DoorDash, Inc.</a> – DoorDash held talks over the past two months to buy grocery delivery service Instacart, according to people familiar with the matter who spoke to The Information. The news website said the talks have fallen apart in recent weeks amid concerns that such a deal would have a difficult time winning regulatory approval. DoorDash rose 2.3% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/HIMS\">Hims &amp; Hers Health Inc.</a> – Hims &amp; Hers lost 3 cents per share for its second quarter, smaller than the 9 cents loss that Wall Street had been anticipating. The telehealth platform operator also reported better-than-expected revenue. The stock leaped 11% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/RXT\">Rackspace Technology</a> – Rackspace beat estimates by 2 cents with an adjusted quarterly profit of 24 cents per share, and the cloud computing company’s revenue also topped forecasts. However, Rackspace also gave weaker-than-expected current-quarter guidance, with the company saying it is in a “transient phase” as it phases out older business segments. Shares slumped 9.3% in premarket action.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Futures tracking the Dow hit a record high on Thursday ahead of earnings reports from companies including Walt Disney and data expected to show a jobs market recovery was on track.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were up 35 points, or 0.1%, S&amp;P 500 E-minis were up 2 points, or 0.05% and Nasdaq 100 E-minis were up 8.5 points, or 0.06%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f35f9eb8d6574ed6eb40236f67b99935\" tg-width=\"579\" tg-height=\"200\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>Rate-sensitive lenders JPMorgan Chase &amp; Co, Wells Fargo &amp; Co, Bank of America Corp and Goldman Sachs Group Inc edged higher before the opening bell.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> – The software platform company matched Wall Street forecasts with adjusted quarterly earnings of 4 cents per share and revenue beating analyst forecasts. Sales rose 49% from a year ago, and the stock rallied 5.7% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/CYBR\">CyberArk</a> – The cybersecurity company earned an adjusted 1 cent per share for its latest quarter, compared with a consensus estimate of 2 cents, while revenue came in above estimates with subscription revenue more than doubling from a year ago. CyberArk shares slid 4.9% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/UTZ\">Utz Brands, Inc.</a> – The snack maker’s stock fell 4.5% in the premarket after it missed estimates by 2 cents with adjusted quarterly earnings of 13 cents per share, although revenue did beat Wall Street forecasts. Utz expects continued strong demand for its products, but also expects costs to remain elevated for the remainder of the year.</p>\n<p><a href=\"https://laohu8.com/S/EBAY\">eBay</a> – eBay beat estimates by 4 cents with adjusted quarterly earnings of 99 cents per share. However, it reported a decline in active buyers and is forecasting lower than expected revenue for the current quarter as overall e-commerce trends soften. eBay fell 1.5% in premarket action.</p>\n<p><a href=\"https://laohu8.com/S/BMBL\">Bumble Inc.</a> – Bumble lost 6 cents per share for its latest quarter, compared with consensus estimates for a 1 cent per-share profit. However, the dating service operator’s revenue topped forecasts as its paying user numbers jumped 20% from a year earlier, and it issued upbeat current-quarter revenue guidance. Bumble gained 1.7% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/SONO\">Sonos Inc</a> – Sonos surged 11.6% in premarket trading after it reported a surprise profit of 12 cents per share, with analysts having expected a quarterly loss of 17 cents per share. The maker of home audio equipment also issued strong current-quarter and full-year sales guidance.</p>\n<p><a href=\"https://laohu8.com/S/OPEN\">Opendoor Technologies Inc</a> – Opendoor soared 19.5% in premarket action after reporting it lost 24 cents per share for its latest quarter, 10 cents less than analysts had been projecting. The home buying and selling company also reported better-than-expected revenue, in addition to issuing an upbeat current-quarter sales forecast.</p>\n<p><a href=\"https://laohu8.com/S/RIDE\">Lordstown Motors Corp.</a> – Lordstown Motors is seeing its shares rally in the premarket after saying it was on track to begin limited production of its Endurance electric pickup truck by the end of September. Lordstown gained 1.6% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/DASH\">DoorDash, Inc.</a> – DoorDash held talks over the past two months to buy grocery delivery service Instacart, according to people familiar with the matter who spoke to The Information. The news website said the talks have fallen apart in recent weeks amid concerns that such a deal would have a difficult time winning regulatory approval. DoorDash rose 2.3% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/HIMS\">Hims &amp; Hers Health Inc.</a> – Hims &amp; Hers lost 3 cents per share for its second quarter, smaller than the 9 cents loss that Wall Street had been anticipating. The telehealth platform operator also reported better-than-expected revenue. The stock leaped 11% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/RXT\">Rackspace Technology</a> – Rackspace beat estimates by 2 cents with an adjusted quarterly profit of 24 cents per share, and the cloud computing company’s revenue also topped forecasts. However, Rackspace also gave weaker-than-expected current-quarter guidance, with the company saying it is in a “transient phase” as it phases out older business segments. Shares slumped 9.3% in premarket action.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119893366","content_text":"Futures tracking the Dow hit a record high on Thursday ahead of earnings reports from companies including Walt Disney and data expected to show a jobs market recovery was on track.\nAt 8:05 a.m. ET, Dow E-minis were up 35 points, or 0.1%, S&P 500 E-minis were up 2 points, or 0.05% and Nasdaq 100 E-minis were up 8.5 points, or 0.06%.\n*Source From Tiger Trade, EST 08:05\nRate-sensitive lenders JPMorgan Chase & Co, Wells Fargo & Co, Bank of America Corp and Goldman Sachs Group Inc edged higher before the opening bell.\nStocks making the biggest moves in the premarket:\nPalantir Technologies Inc. – The software platform company matched Wall Street forecasts with adjusted quarterly earnings of 4 cents per share and revenue beating analyst forecasts. Sales rose 49% from a year ago, and the stock rallied 5.7% in the premarket.\nCyberArk – The cybersecurity company earned an adjusted 1 cent per share for its latest quarter, compared with a consensus estimate of 2 cents, while revenue came in above estimates with subscription revenue more than doubling from a year ago. CyberArk shares slid 4.9% in premarket trading.\nUtz Brands, Inc. – The snack maker’s stock fell 4.5% in the premarket after it missed estimates by 2 cents with adjusted quarterly earnings of 13 cents per share, although revenue did beat Wall Street forecasts. Utz expects continued strong demand for its products, but also expects costs to remain elevated for the remainder of the year.\neBay – eBay beat estimates by 4 cents with adjusted quarterly earnings of 99 cents per share. However, it reported a decline in active buyers and is forecasting lower than expected revenue for the current quarter as overall e-commerce trends soften. eBay fell 1.5% in premarket action.\nBumble Inc. – Bumble lost 6 cents per share for its latest quarter, compared with consensus estimates for a 1 cent per-share profit. However, the dating service operator’s revenue topped forecasts as its paying user numbers jumped 20% from a year earlier, and it issued upbeat current-quarter revenue guidance. Bumble gained 1.7% in the premarket.\nSonos Inc – Sonos surged 11.6% in premarket trading after it reported a surprise profit of 12 cents per share, with analysts having expected a quarterly loss of 17 cents per share. The maker of home audio equipment also issued strong current-quarter and full-year sales guidance.\nOpendoor Technologies Inc – Opendoor soared 19.5% in premarket action after reporting it lost 24 cents per share for its latest quarter, 10 cents less than analysts had been projecting. The home buying and selling company also reported better-than-expected revenue, in addition to issuing an upbeat current-quarter sales forecast.\nLordstown Motors Corp. – Lordstown Motors is seeing its shares rally in the premarket after saying it was on track to begin limited production of its Endurance electric pickup truck by the end of September. Lordstown gained 1.6% in the premarket.\nDoorDash, Inc. – DoorDash held talks over the past two months to buy grocery delivery service Instacart, according to people familiar with the matter who spoke to The Information. The news website said the talks have fallen apart in recent weeks amid concerns that such a deal would have a difficult time winning regulatory approval. DoorDash rose 2.3% in premarket trading.\nHims & Hers Health Inc. – Hims & Hers lost 3 cents per share for its second quarter, smaller than the 9 cents loss that Wall Street had been anticipating. The telehealth platform operator also reported better-than-expected revenue. The stock leaped 11% in the premarket.\nRackspace Technology – Rackspace beat estimates by 2 cents with an adjusted quarterly profit of 24 cents per share, and the cloud computing company’s revenue also topped forecasts. However, Rackspace also gave weaker-than-expected current-quarter guidance, with the company saying it is in a “transient phase” as it phases out older business segments. Shares slumped 9.3% in premarket action.","news_type":1},"isVote":1,"tweetType":1,"viewCount":6,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893833716,"gmtCreate":1628253506135,"gmtModify":1631889829174,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/893833716","repostId":"1195593033","repostType":4,"isVote":1,"tweetType":1,"viewCount":64,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899398773,"gmtCreate":1628157507292,"gmtModify":1631889829178,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"💪","listText":"💪","text":"💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899398773","repostId":"1122849992","repostType":4,"repost":{"id":"1122849992","pubTimestamp":1628152495,"share":"https://www.laohu8.com/m/news/1122849992?lang=&edition=full","pubTime":"2021-08-05 16:34","market":"us","language":"en","title":"Roku Slides as Reopening Leads to Less Streaming Viewing","url":"https://stock-news.laohu8.com/highlight/detail?id=1122849992","media":"Bloomberg","summary":"(Bloomberg) -- Roku Inc. shares tumbled in premarket trading on Thursday after it reported second-qu","content":"<p>(Bloomberg) -- Roku Inc. shares tumbled in premarket trading on Thursday after it reported second-quarter results that missed expectations on key metrics.</p>\n<p>The video-streaming platform company reported 55.1 million active customer accounts for the quarter and 17.4 billion streaming hours. The Bloomberg Consensus estimate had been for 55.8 million active customer accounts and 19.19 billion streaming hours.</p>\n<p>“In the near term, the varying rates of recovery from the pandemic around the world continue to present an uncertain operating environment,” the company wrote in a letter to shareholders. It added that the loosening of restrictions related to the pandemic had led to a broader secular decline in overall TV viewing.</p>\n<p>Shares fell over&nbsp;8% in&nbsp;premarket&nbsp;trading&nbsp;Thursday.</p>\n<p><img src=\"https://static.tigerbbs.com/c5160ff6c7c1b2e44a60bb3dc25b23ca\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n<p>“We will definitely face difficult year-over-year comparisons in the back half of the year in terms of active accounts and streaming hours, but streaming video is a secular trend, not just a pandemic trend,” Steve Louden, Roku’s chief financial officer, said in an interview. “We feel good about the continued shift to streaming by viewers, and about advertising dollars continuing to move to streaming” and away from linear TV.</p>\n<p>Roku forecast third-quarter net revenue of $675 million to $685 million. The analyst consensus is for revenue of $646.5 million.</p>\n<p>For the second quarter, Roku revenue came in at $645.1 million, above the $613.1 million estimate.</p>\n<p>Shares of Roku are down about 12% from a record close hit in July, though it remains up nearly 50% from a May low, based on its most recent close. The stock rose 0.6% in Wednesday’s regular session.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roku Slides as Reopening Leads to Less Streaming Viewing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoku Slides as Reopening Leads to Less Streaming Viewing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 16:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roku-slides-accounts-streaming-hours-202603181.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Roku Inc. shares tumbled in premarket trading on Thursday after it reported second-quarter results that missed expectations on key metrics.\nThe video-streaming platform company reported...</p>\n\n<a href=\"https://finance.yahoo.com/news/roku-slides-accounts-streaming-hours-202603181.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ROKU":"Roku Inc"},"source_url":"https://finance.yahoo.com/news/roku-slides-accounts-streaming-hours-202603181.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122849992","content_text":"(Bloomberg) -- Roku Inc. shares tumbled in premarket trading on Thursday after it reported second-quarter results that missed expectations on key metrics.\nThe video-streaming platform company reported 55.1 million active customer accounts for the quarter and 17.4 billion streaming hours. The Bloomberg Consensus estimate had been for 55.8 million active customer accounts and 19.19 billion streaming hours.\n“In the near term, the varying rates of recovery from the pandemic around the world continue to present an uncertain operating environment,” the company wrote in a letter to shareholders. It added that the loosening of restrictions related to the pandemic had led to a broader secular decline in overall TV viewing.\nShares fell over 8% in premarket trading Thursday.\n\n“We will definitely face difficult year-over-year comparisons in the back half of the year in terms of active accounts and streaming hours, but streaming video is a secular trend, not just a pandemic trend,” Steve Louden, Roku’s chief financial officer, said in an interview. “We feel good about the continued shift to streaming by viewers, and about advertising dollars continuing to move to streaming” and away from linear TV.\nRoku forecast third-quarter net revenue of $675 million to $685 million. The analyst consensus is for revenue of $646.5 million.\nFor the second quarter, Roku revenue came in at $645.1 million, above the $613.1 million estimate.\nShares of Roku are down about 12% from a record close hit in July, though it remains up nearly 50% from a May low, based on its most recent close. The stock rose 0.6% in Wednesday’s regular session.","news_type":1},"isVote":1,"tweetType":1,"viewCount":242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899919832,"gmtCreate":1628150806026,"gmtModify":1631889829181,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Can I still buy Moderna?","listText":"Can I still buy Moderna?","text":"Can I still buy Moderna?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/899919832","repostId":"1129912476","repostType":4,"isVote":1,"tweetType":1,"viewCount":16,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890185008,"gmtCreate":1628086971304,"gmtModify":1631889829184,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"We need more factories 👍","listText":"We need more factories 👍","text":"We need more factories 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/890185008","repostId":"2156060681","repostType":4,"repost":{"id":"2156060681","pubTimestamp":1628085780,"share":"https://www.laohu8.com/m/news/2156060681?lang=&edition=full","pubTime":"2021-08-04 22:03","market":"us","language":"en","title":"Tech Companies Are Facing a Global Chip Shortage: 5 Tips for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2156060681","media":"Motley Fool","summary":"The chip shortage is creating new opportunities and risks for investors.","content":"<blockquote>\n The chip shortage is creating new opportunities and risks for investors.\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>The global chip shortage has the potential to last through 2023.</li>\n <li>Investors should dig deeper into the semiconductor sector to understand those challenges.</li>\n <li>Investors should recognize the near-term headwinds for companies relying on a steady supply of new chips.</li>\n</ul>\n<p>The global chip shortage started in 2018 and 2019 as escalating trade conflicts disrupted semiconductor supply chains, then worsened in 2020 as the pandemic exacerbated those disruptions. Many top chipmakers and analysts expect the ongoing crisis to last through 2023.</p>\n<p>That shortage is generating tailwinds and headwinds for certain companies, but it can be tough for investors to tune out the noise and separate the winners from the losers. Let's examine five main aspects of the chip shortage -- and how they could affect certain sectors and stocks.</p>\n<h3>1. Understand the secular tailwinds</h3>\n<p>Even if the trade war and pandemic didn't happen, the market's demand for chips would still be elevated today. <a href=\"https://laohu8.com/S/NGD\">New</a> 5G devices, gaming consoles, connected and driverless cars, and Internet of Things (IoT) gadgets all require increasing numbers of more advanced chips. Data centers are also upgrading their servers to deal with the surging usage of cloud, machine learning, and artificial intelligence (AI) services.</p>\n<p>However, the pandemic also accelerated sales of stay-at-home consumer electronics such as PCs and gaming consoles, while disrupting the available supply of chips. Those unexpected twists made it even tougher for chipmakers to keep up with the market's insatiable appetite for new chips.</p>\n<h3>2. Understand the geopolitical tensions</h3>\n<p>The tech war between the U.S. and China is causing headaches for many chipmakers. For example, <b><a href=\"https://laohu8.com/S/TSM\">Taiwan Semiconductor Manufacturing</a> Company</b> (NYSE:TSM), the world's top contract chipmaker, was forced to stop accepting orders from <b>Huawei</b> after the U.S. blacklisted the Chinese tech giant. U.S. chipmakers like <b><a href=\"https://laohu8.com/S/SWKS\">Skyworks Solutions</a></b> and <b><a href=\"https://laohu8.com/S/MU\">Micron Technology</a></b> were also forced to cut ties with Huawei.</p>\n<p>That decoupling caused China to aggressively subsidize its domestic chipmakers, while its regulators threatened to delay big deals -- such as <b>Nvidia</b>'s (NASDAQ:NVDA) planned purchase of Arm -- that benefit <a href=\"https://laohu8.com/S/AFG\">American</a> chipmakers. Meanwhile, the U.S. has granted subsidies to TSMC to build new plants in Arizona, and will likely subsidize <b><a href=\"https://laohu8.com/S/INTC\">Intel</a></b>'s (NASDAQ:INTC) plans to expand its domestic foundries.</p>\n<h3>3. Understand the different types of chipmakers</h3>\n<p>Investors shouldn't touch any chip stocks until they understand the differences between integrated device manufacturers (IDMs), fabless chipmakers, chip designers, and third-party foundries.</p>\n<p>IDMs design, manufacture, and sell their own chips. Intel, Skyworks, and <b><a href=\"https://laohu8.com/S/TXN\">Texas Instruments</a></b>&nbsp;are all IDMs -- but Intel manufactures smaller and more complex chips than those other two chipmakers.</p>\n<p>Fabless chipmakers design their own chips but outsource the production to third-party foundries. These chipmakers -- which include Nvidia, <b><a href=\"https://laohu8.com/S/AEIS\">Advanced</a> Micro Devices</b>, and <b><a href=\"https://laohu8.com/S/QCOM\">Qualcomm</a></b> -- adopt this model because it's become too expensive to mass produce advanced chips on their own.</p>\n<p>Chip designers license their designs to other chipmakers instead of manufacturing any chips. The industry's most important chip designer is arguably Arm Holdings, which provides designs for most of the world's mobile chips. That's why Nvidia's planned takeover of Arm is so controversial.</p>\n<p>Lastly, third-party foundries do the heavy lifting for fabless chipmakers. TSMC and <b>Samsung</b>are the world's two most advanced contract chipmakers -- but Intel is trying to catch up with aggressive investments in its third-party foundry services. These leading foundries represent bottlenecks in the semiconductor market, and the chip shortage won't be resolved until they expand their capacity.</p>\n<p><img src=\"https://static.tigerbbs.com/36e7c524b510f3ddf875d48fa2f3ac29\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>4. Evaluate the revenue growth vs. the rising costs</h3>\n<p>The global chip shortage seems to make TSMC a great investment since it's a linchpin of the market, but investors should realize it needs to significantly boost its capex to expand its capacity while maintaining its lead in the \"process race\" of creating smaller and more advanced chips.</p>\n<p>TSMC plans to boost its capex from $17.2 billion in 2020 to approximately $30 billion this year, then collectively spend roughly $100 billion on its expansion over the next three years. Investors should weigh those rising costs against its projected revenue growth to see if the stock is worth buying. They should also view Intel and Samsung (which isn't available on U.S. exchanges) through the same lens.</p>\n<p>Investors should also see where all that spending is going. One of those top beneficiaries is<b> ASML Holding</b> (NASDAQ:ASML), the Dutch semiconductor equipment maker that has monopolized the entire market for high-end EUV (extreme ultraviolet) systems -- which TSMC, Samsung, and Intel all need to manufacture their smallest and most advanced chips.</p>\n<p>Therefore, it might make more sense to invest in ASML, another linchpin of the global semiconductor market, instead of other chipmakers as a long-term play on the ongoing chip shortage.</p>\n<h3>5. Understand which companies are affected the most</h3>\n<p>In addition to treading carefully with chipmakers and equipment makers during the shortage, investors should understand how the current bottlenecks could affect consumer-facing companies like<b> <a href=\"https://laohu8.com/S/AAPL\">Apple</a></b> (NASDAQ:AAPL), <b><a href=\"https://laohu8.com/S/SONY\">Sony</a></b> , and <b>Nintendo</b>. Apple expects the chip shortage to impact its iPhone shipments this year, while <a href=\"https://laohu8.com/S/SONY\">Sony</a> and Nintendo expect those headwinds to throttle their shipments of PS5 and Switch consoles, respectively. The shortage is also disrupting the production of new vehicles.</p>\n<p>Most of these companies should recover since there's plenty of pent-up demand for their products, but investors shouldn't ignore the near-term headwinds. Investors who want to profit from the shortage over the next two years should dive deeper into the semiconductor sector instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tech Companies Are Facing a Global Chip Shortage: 5 Tips for Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTech Companies Are Facing a Global Chip Shortage: 5 Tips for Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 22:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/04/tech-companies-facing-global-chip-shortage-5-tips/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The chip shortage is creating new opportunities and risks for investors.\n\nKey Points\n\nThe global chip shortage has the potential to last through 2023.\nInvestors should dig deeper into the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/04/tech-companies-facing-global-chip-shortage-5-tips/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SSNLF":"三星电子","AMD":"美国超微公司","QCOM":"高通","AAPL":"苹果","SWKS":"思佳讯","INTC":"英特尔","MU":"美光科技","SONY":"索尼","ASML":"阿斯麦","TXN":"德州仪器","NVDA":"英伟达","TSM":"台积电"},"source_url":"https://www.fool.com/investing/2021/08/04/tech-companies-facing-global-chip-shortage-5-tips/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156060681","content_text":"The chip shortage is creating new opportunities and risks for investors.\n\nKey Points\n\nThe global chip shortage has the potential to last through 2023.\nInvestors should dig deeper into the semiconductor sector to understand those challenges.\nInvestors should recognize the near-term headwinds for companies relying on a steady supply of new chips.\n\nThe global chip shortage started in 2018 and 2019 as escalating trade conflicts disrupted semiconductor supply chains, then worsened in 2020 as the pandemic exacerbated those disruptions. Many top chipmakers and analysts expect the ongoing crisis to last through 2023.\nThat shortage is generating tailwinds and headwinds for certain companies, but it can be tough for investors to tune out the noise and separate the winners from the losers. Let's examine five main aspects of the chip shortage -- and how they could affect certain sectors and stocks.\n1. Understand the secular tailwinds\nEven if the trade war and pandemic didn't happen, the market's demand for chips would still be elevated today. New 5G devices, gaming consoles, connected and driverless cars, and Internet of Things (IoT) gadgets all require increasing numbers of more advanced chips. Data centers are also upgrading their servers to deal with the surging usage of cloud, machine learning, and artificial intelligence (AI) services.\nHowever, the pandemic also accelerated sales of stay-at-home consumer electronics such as PCs and gaming consoles, while disrupting the available supply of chips. Those unexpected twists made it even tougher for chipmakers to keep up with the market's insatiable appetite for new chips.\n2. Understand the geopolitical tensions\nThe tech war between the U.S. and China is causing headaches for many chipmakers. For example, Taiwan Semiconductor Manufacturing Company (NYSE:TSM), the world's top contract chipmaker, was forced to stop accepting orders from Huawei after the U.S. blacklisted the Chinese tech giant. U.S. chipmakers like Skyworks Solutions and Micron Technology were also forced to cut ties with Huawei.\nThat decoupling caused China to aggressively subsidize its domestic chipmakers, while its regulators threatened to delay big deals -- such as Nvidia's (NASDAQ:NVDA) planned purchase of Arm -- that benefit American chipmakers. Meanwhile, the U.S. has granted subsidies to TSMC to build new plants in Arizona, and will likely subsidize Intel's (NASDAQ:INTC) plans to expand its domestic foundries.\n3. Understand the different types of chipmakers\nInvestors shouldn't touch any chip stocks until they understand the differences between integrated device manufacturers (IDMs), fabless chipmakers, chip designers, and third-party foundries.\nIDMs design, manufacture, and sell their own chips. Intel, Skyworks, and Texas Instruments are all IDMs -- but Intel manufactures smaller and more complex chips than those other two chipmakers.\nFabless chipmakers design their own chips but outsource the production to third-party foundries. These chipmakers -- which include Nvidia, Advanced Micro Devices, and Qualcomm -- adopt this model because it's become too expensive to mass produce advanced chips on their own.\nChip designers license their designs to other chipmakers instead of manufacturing any chips. The industry's most important chip designer is arguably Arm Holdings, which provides designs for most of the world's mobile chips. That's why Nvidia's planned takeover of Arm is so controversial.\nLastly, third-party foundries do the heavy lifting for fabless chipmakers. TSMC and Samsungare the world's two most advanced contract chipmakers -- but Intel is trying to catch up with aggressive investments in its third-party foundry services. These leading foundries represent bottlenecks in the semiconductor market, and the chip shortage won't be resolved until they expand their capacity.\n\nImage source: Getty Images.\n4. Evaluate the revenue growth vs. the rising costs\nThe global chip shortage seems to make TSMC a great investment since it's a linchpin of the market, but investors should realize it needs to significantly boost its capex to expand its capacity while maintaining its lead in the \"process race\" of creating smaller and more advanced chips.\nTSMC plans to boost its capex from $17.2 billion in 2020 to approximately $30 billion this year, then collectively spend roughly $100 billion on its expansion over the next three years. Investors should weigh those rising costs against its projected revenue growth to see if the stock is worth buying. They should also view Intel and Samsung (which isn't available on U.S. exchanges) through the same lens.\nInvestors should also see where all that spending is going. One of those top beneficiaries is ASML Holding (NASDAQ:ASML), the Dutch semiconductor equipment maker that has monopolized the entire market for high-end EUV (extreme ultraviolet) systems -- which TSMC, Samsung, and Intel all need to manufacture their smallest and most advanced chips.\nTherefore, it might make more sense to invest in ASML, another linchpin of the global semiconductor market, instead of other chipmakers as a long-term play on the ongoing chip shortage.\n5. Understand which companies are affected the most\nIn addition to treading carefully with chipmakers and equipment makers during the shortage, investors should understand how the current bottlenecks could affect consumer-facing companies like Apple (NASDAQ:AAPL), Sony , and Nintendo. Apple expects the chip shortage to impact its iPhone shipments this year, while Sony and Nintendo expect those headwinds to throttle their shipments of PS5 and Switch consoles, respectively. The shortage is also disrupting the production of new vehicles.\nMost of these companies should recover since there's plenty of pent-up demand for their products, but investors shouldn't ignore the near-term headwinds. Investors who want to profit from the shortage over the next two years should dive deeper into the semiconductor sector instead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890349890,"gmtCreate":1628084819710,"gmtModify":1631889829185,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"We need this 👍","listText":"We need this 👍","text":"We need this 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/890349890","repostId":"1108635314","repostType":4,"repost":{"id":"1108635314","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628084737,"share":"https://www.laohu8.com/m/news/1108635314?lang=&edition=full","pubTime":"2021-08-04 21:45","market":"us","language":"en","title":"AMD gained over 5% and reached record high","url":"https://stock-news.laohu8.com/highlight/detail?id=1108635314","media":"Tiger Newspress","summary":"(August 4) AMD gained over 5% and reached record high.","content":"<p>(August 4)&nbsp;<a href=\"https://laohu8.com/S/AMD\">AMD</a> gained over 5% and reached record high.</p>\n<p><img src=\"https://static.tigerbbs.com/8b23aa43d6e0816bc9aeaa95fc08fcd6\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD gained over 5% and reached record high</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD gained over 5% and reached record high\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-04 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 4)&nbsp;<a href=\"https://laohu8.com/S/AMD\">AMD</a> gained over 5% and reached record high.</p>\n<p><img src=\"https://static.tigerbbs.com/8b23aa43d6e0816bc9aeaa95fc08fcd6\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108635314","content_text":"(August 4) AMD gained over 5% and reached record high.","news_type":1},"isVote":1,"tweetType":1,"viewCount":52,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890960248,"gmtCreate":1628076808384,"gmtModify":1631889829186,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Great news from Pfizer 👏🏻 well done","listText":"Great news from Pfizer 👏🏻 well done","text":"Great news from Pfizer 👏🏻 well done","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/890960248","repostId":"2156103241","repostType":2,"isVote":1,"tweetType":1,"viewCount":45,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807457737,"gmtCreate":1628052644529,"gmtModify":1631889829190,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"That’s good&nbsp;","listText":"That’s good&nbsp;","text":"That’s good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807457737","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","pubTimestamp":1628045612,"share":"https://www.laohu8.com/m/news/1124757232?lang=&edition=full","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Pfizer might surprise to the upside.</li>\n <li>Inari Medical is growing like gangbusters.</li>\n <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li>\n</ul>\n<p>COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p>\n<p>A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<h3><b>Pfizer: More room to run</b></h3>\n<p><b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p>\n<p>Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p>\n<p>There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p>\n<p>Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p>\n<p>The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p>\n<p>Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p>\n<h3><b>Inari Medical: Skyrocketing Sales</b></h3>\n<p><b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p>\n<p>This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p>\n<p>Not to mention the company's results thus far for blood clots in the lung are spectacular:</p>\n<ul>\n <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>\n <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>\n <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>\n <li>No ICU stays are required after the procedure.</li>\n</ul>\n<p>Add it all up, and Inari's retrieval device seems like an obvious choice.</p>\n<p>The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p>\n<p>Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p>\n<h3><b>Novavax: How high can it go?</b></h3>\n<p><b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p>\n<p>Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p>\n<p>Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p>\n<p>In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p>\n<p>Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 10:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","NARI":"Inari Medical, Inc."},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804966742,"gmtCreate":1627916792786,"gmtModify":1633755274197,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"I am watching 😳","listText":"I am watching 😳","text":"I am watching 😳","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804966742","repostId":"1196763976","repostType":4,"repost":{"id":"1196763976","pubTimestamp":1627903466,"share":"https://www.laohu8.com/m/news/1196763976?lang=&edition=full","pubTime":"2021-08-02 19:24","market":"us","language":"en","title":"When Will Stocks Drop? Watch Profit Margins (and Get Nervous)","url":"https://stock-news.laohu8.com/highlight/detail?id=1196763976","media":"Bloomberg","summary":"The evidence is mounting that companies are having a harder time passing off cost increases to their","content":"<blockquote>\n The evidence is mounting that companies are having a harder time passing off cost&nbsp;increases to their customers.\n</blockquote>\n<p>Want to know where the S&amp;P 500 Index may be headed after reaching another record high? Take a look at profit margins.</p>\n<p>Operating margin forecasts are a strong leading indicator of stock prices. A decline in such outlooks preceded routs in the S&amp;P 500 in 2011, 2015, 2018 and 2020. What’s concerning now is that analysts have stopped raising their forecasts, and if they begin to lower them, it's likely to lead to a dip in the broader market again. And it’s not like there’s a lot of room for further improvement in margins, defined as earnings before interest and taxes divided by sales. The consensus among analysts is that they will expand to 16.7% over the next 12 months, topping the previous record of 16.4% set in 2018.</p>\n<p>The relationship between S&amp;P 500 profitability and inflation indicators is murky at best, but recent spikes in the producer price index and a smaller increase in the consumer price index is enough to raise a caution flag for equity margin expansion potential for the next few quarters. At its peak in April, the PPI rose 9.5% from a year earlier, almost 3 standard deviations above its average over the past 30 years. (It rose 9.4% in June.) From 2010 to 2019, the median estimate of where operating margins would be 12 months into the future for S&amp;P 500 members were negatively correlated to changes in PPI. The current coefficient of minus 0.22 suggests gains in corporate profitability are likely to stall or even fall as producer prices continue to rise.</p>\n<p><b>Watch Those Margins</b></p>\n<p>Past dips in forecasted profit margins have lined up with pull-backs in equities.</p>\n<p><img src=\"https://static.tigerbbs.com/2dbda2c0b9394d518fdc8af7d693c8f3\" tg-width=\"644\" tg-height=\"283\" width=\"100%\" height=\"auto\">The difference between the PPI and CPI suggests companies are unable to pass cost increases on to consumers. The spread between the two fell to a record low of minus 5.3 percentage points in April, and is still strongly inverted at minus 4.1 percentage points. Over the last 30 years, the operating margin for the S&amp;P 500 narrowed 6.5 percentage points on average one year after the gap fell below minus 2 percentage points. Not only that, but in the year after the spread breached minus 2 percentage points, the S&amp;P fell 2.5% on average.</p>\n<p>Analysts are getting nervous. They have cut their margin estimates for a quarter of S&amp;P 500 members in the last three months. Their stocks were down 0.63%, compared with a gain of 2.20% for the index and a 3.30% increase for companies with rising margin forecasts. Slicing the index into quintiles based on changes in operating margin shows that companies with the largest declines had a median stock-price decline of 0.5%, versus a gain of 3.9% for those with the greatest expansion in consensus estimates.</p>\n<p>Industries with the most negative margin pressures are likely to be those that investors historically consider “defensive,” such as health care, utilities and consumer staples. Large companies involved in pharmaceuticals, biotechnology and life sciences, household and personal products, and utilities have historically fared worst when producer prices outrun consumer prices, and these are where margin forecasts gave dropped the most over the last three months. Margins forecasts continue to rise for the more cyclically-oriented segments of the equity market, with media, consumer services, transportation and oil and gas industries having the largest gains.</p>\n<p><b>Winners and Losers</b></p>\n<p>Cyclically-oriented sectors are relatively immune from broad profit margin compression.</p>\n<p><img src=\"https://static.tigerbbs.com/884366efc825eccec2878fcd4b3f0912\" tg-width=\"640\" tg-height=\"533\" width=\"100%\" height=\"auto\">Though consensus expectations imply smooth sailing, companies are set up for a more challenging margin outlook as revenue growth rates likely fade, but inflation pressures remain relatively high given persistent uncertainty in the supply chain. Against this backdrop, currently selective industry margin weaknesses may start to spread to more industries, resulting in degradation of margin forecasts for the index at large. Given these estimates are a strong strong leading indicator of stock-price direction, margin trends may be a critical risk to the equity market in the months ahead.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>When Will Stocks Drop? Watch Profit Margins (and Get Nervous)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhen Will Stocks Drop? Watch Profit Margins (and Get Nervous)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 19:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The evidence is mounting that companies are having a harder time passing off cost increases to their customers.\n\nWant to know where the S&P 500 Index may be headed after reaching another record high? ...</p>\n\n<a href=\"https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196763976","content_text":"The evidence is mounting that companies are having a harder time passing off cost increases to their customers.\n\nWant to know where the S&P 500 Index may be headed after reaching another record high? Take a look at profit margins.\nOperating margin forecasts are a strong leading indicator of stock prices. A decline in such outlooks preceded routs in the S&P 500 in 2011, 2015, 2018 and 2020. What’s concerning now is that analysts have stopped raising their forecasts, and if they begin to lower them, it's likely to lead to a dip in the broader market again. And it’s not like there’s a lot of room for further improvement in margins, defined as earnings before interest and taxes divided by sales. The consensus among analysts is that they will expand to 16.7% over the next 12 months, topping the previous record of 16.4% set in 2018.\nThe relationship between S&P 500 profitability and inflation indicators is murky at best, but recent spikes in the producer price index and a smaller increase in the consumer price index is enough to raise a caution flag for equity margin expansion potential for the next few quarters. At its peak in April, the PPI rose 9.5% from a year earlier, almost 3 standard deviations above its average over the past 30 years. (It rose 9.4% in June.) From 2010 to 2019, the median estimate of where operating margins would be 12 months into the future for S&P 500 members were negatively correlated to changes in PPI. The current coefficient of minus 0.22 suggests gains in corporate profitability are likely to stall or even fall as producer prices continue to rise.\nWatch Those Margins\nPast dips in forecasted profit margins have lined up with pull-backs in equities.\nThe difference between the PPI and CPI suggests companies are unable to pass cost increases on to consumers. The spread between the two fell to a record low of minus 5.3 percentage points in April, and is still strongly inverted at minus 4.1 percentage points. Over the last 30 years, the operating margin for the S&P 500 narrowed 6.5 percentage points on average one year after the gap fell below minus 2 percentage points. Not only that, but in the year after the spread breached minus 2 percentage points, the S&P fell 2.5% on average.\nAnalysts are getting nervous. They have cut their margin estimates for a quarter of S&P 500 members in the last three months. Their stocks were down 0.63%, compared with a gain of 2.20% for the index and a 3.30% increase for companies with rising margin forecasts. Slicing the index into quintiles based on changes in operating margin shows that companies with the largest declines had a median stock-price decline of 0.5%, versus a gain of 3.9% for those with the greatest expansion in consensus estimates.\nIndustries with the most negative margin pressures are likely to be those that investors historically consider “defensive,” such as health care, utilities and consumer staples. Large companies involved in pharmaceuticals, biotechnology and life sciences, household and personal products, and utilities have historically fared worst when producer prices outrun consumer prices, and these are where margin forecasts gave dropped the most over the last three months. Margins forecasts continue to rise for the more cyclically-oriented segments of the equity market, with media, consumer services, transportation and oil and gas industries having the largest gains.\nWinners and Losers\nCyclically-oriented sectors are relatively immune from broad profit margin compression.\nThough consensus expectations imply smooth sailing, companies are set up for a more challenging margin outlook as revenue growth rates likely fade, but inflation pressures remain relatively high given persistent uncertainty in the supply chain. Against this backdrop, currently selective industry margin weaknesses may start to spread to more industries, resulting in degradation of margin forecasts for the index at large. Given these estimates are a strong strong leading indicator of stock-price direction, margin trends may be a critical risk to the equity market in the months ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":83,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804966953,"gmtCreate":1627916764572,"gmtModify":1633755274725,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Hurray 🎉","listText":"Hurray 🎉","text":"Hurray 🎉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/804966953","repostId":"1155818598","repostType":4,"isVote":1,"tweetType":1,"viewCount":11,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":890349890,"gmtCreate":1628084819710,"gmtModify":1631889829185,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"We need this 👍","listText":"We need this 👍","text":"We need this 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/890349890","repostId":"1108635314","repostType":4,"repost":{"id":"1108635314","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628084737,"share":"https://www.laohu8.com/m/news/1108635314?lang=&edition=full","pubTime":"2021-08-04 21:45","market":"us","language":"en","title":"AMD gained over 5% and reached record high","url":"https://stock-news.laohu8.com/highlight/detail?id=1108635314","media":"Tiger Newspress","summary":"(August 4) AMD gained over 5% and reached record high.","content":"<p>(August 4)&nbsp;<a href=\"https://laohu8.com/S/AMD\">AMD</a> gained over 5% and reached record high.</p>\n<p><img src=\"https://static.tigerbbs.com/8b23aa43d6e0816bc9aeaa95fc08fcd6\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD gained over 5% and reached record high</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD gained over 5% and reached record high\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-04 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 4)&nbsp;<a href=\"https://laohu8.com/S/AMD\">AMD</a> gained over 5% and reached record high.</p>\n<p><img src=\"https://static.tigerbbs.com/8b23aa43d6e0816bc9aeaa95fc08fcd6\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108635314","content_text":"(August 4) AMD gained over 5% and reached record high.","news_type":1},"isVote":1,"tweetType":1,"viewCount":52,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":876274192,"gmtCreate":1637327527189,"gmtModify":1637327527331,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"I just got my Moderna booster 💪","listText":"I just got my Moderna booster 💪","text":"I just got my Moderna booster 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876274192","repostId":"1138047553","repostType":2,"repost":{"id":"1138047553","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1},"isVote":1,"tweetType":1,"viewCount":708,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":105438328,"gmtCreate":1620315103564,"gmtModify":1634206123547,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Yes, do the 4 thing now&nbsp;","listText":"Yes, do the 4 thing now&nbsp;","text":"Yes, do the 4 thing now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/105438328","repostId":"2133387578","repostType":4,"repost":{"id":"2133387578","pubTimestamp":1620296700,"share":"https://www.laohu8.com/m/news/2133387578?lang=&edition=full","pubTime":"2021-05-06 18:25","market":"us","language":"en","title":"Think Stocks Will Crash in May? Do These 4 Things Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2133387578","media":"Motley Fool","summary":"Stock market downturns can be daunting. Here's what you need to do to prepare.","content":"<p>When will the stock market crash? That's the big question on many investors' minds at a time when stocks are, across the board, pretty overvalued. In fact, if the stock market doesn't tank completely in the near term, investors should at the very least begin bracing for a correction, where stock values drop 10% or more.</p>\n<p>Of course, the idea of a stock market crash can be very scary, especially if you're a newer investor and you haven't experienced <a href=\"https://laohu8.com/S/AONE\">one</a> before. But rather than allow yourself to get spooked, you're better off taking action. Here are a few crucial moves to make if you're worried that May is when the stock market will finally take a major turn for the worse.</p>\n<h2>1. Pad your emergency savings</h2>\n<p>What does the amount of money you have in the bank have to do with your stock portfolio? A lot, actually. If you secure your emergency fund so you have ample cash to cover unplanned expenses, you won't have to tap your investments out of desperation. That could, in turn, prevent you from needing to liquidate stocks at a time when their value has dropped substantially.</p>\n<h2>2. Diversify</h2>\n<p>A diverse portfolio could help you ride out a stock market crash, so if you're heavily invested in <a href=\"https://laohu8.com/S/AONE.U\">one</a> or two market segments right now, take the opportunity to branch out -- before things take a turn for the worse. Diversifying could simply mean buying stocks in sectors you're not currently invested in. Or you could load up on some index funds or exchange-traded funds (ETFs) that give you access to the broader market. For example, if you invest in an <b>S&amp;P 500</b> index fund or ETF, you'll effectively be putting money into the 500 largest publicly traded companies on the market. It doesn't get much more diverse than that.</p>\n<h2>3. Add dividend stocks to your portfolio</h2>\n<p>Companies that pay dividends tend to do so even when stock values are down. And that's a good way to hedge your bets. If your portfolio takes a hit, you can offset those losses with incoming dividend payments, and that's money you'll have the option to cash out and use as needed or reinvest.</p>\n<h2>4. Stockpile some cash</h2>\n<p>Market crashes tend to spell opportunity, and so it's important to have cash at the ready for when stocks go on sale. While your first priority should be to shore up your emergency fund, if you're also able to divert some extra cash to your brokerage account, you'll put yourself in a great position to pounce while stocks are temporarily discounted.</p>\n<p>Even if you're a seasoned investor who follows the market closely, you probably won't be able to predict exactly when the stock market will crash next. While a May crash is certainly possible, it's also certainly not a given. But rather than spin your wheels trying to determine when that crash is coming, you should instead focus your energy on checking off the boxes above. That way, you'll really be ready for whatever is ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Think Stocks Will Crash in May? Do These 4 Things Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThink Stocks Will Crash in May? Do These 4 Things Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 18:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/06/think-stocks-will-crash-in-may-do-these-4-things-n/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When will the stock market crash? That's the big question on many investors' minds at a time when stocks are, across the board, pretty overvalued. In fact, if the stock market doesn't tank completely ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/06/think-stocks-will-crash-in-may-do-these-4-things-n/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/05/06/think-stocks-will-crash-in-may-do-these-4-things-n/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2133387578","content_text":"When will the stock market crash? That's the big question on many investors' minds at a time when stocks are, across the board, pretty overvalued. In fact, if the stock market doesn't tank completely in the near term, investors should at the very least begin bracing for a correction, where stock values drop 10% or more.\nOf course, the idea of a stock market crash can be very scary, especially if you're a newer investor and you haven't experienced one before. But rather than allow yourself to get spooked, you're better off taking action. Here are a few crucial moves to make if you're worried that May is when the stock market will finally take a major turn for the worse.\n1. Pad your emergency savings\nWhat does the amount of money you have in the bank have to do with your stock portfolio? A lot, actually. If you secure your emergency fund so you have ample cash to cover unplanned expenses, you won't have to tap your investments out of desperation. That could, in turn, prevent you from needing to liquidate stocks at a time when their value has dropped substantially.\n2. Diversify\nA diverse portfolio could help you ride out a stock market crash, so if you're heavily invested in one or two market segments right now, take the opportunity to branch out -- before things take a turn for the worse. Diversifying could simply mean buying stocks in sectors you're not currently invested in. Or you could load up on some index funds or exchange-traded funds (ETFs) that give you access to the broader market. For example, if you invest in an S&P 500 index fund or ETF, you'll effectively be putting money into the 500 largest publicly traded companies on the market. It doesn't get much more diverse than that.\n3. Add dividend stocks to your portfolio\nCompanies that pay dividends tend to do so even when stock values are down. And that's a good way to hedge your bets. If your portfolio takes a hit, you can offset those losses with incoming dividend payments, and that's money you'll have the option to cash out and use as needed or reinvest.\n4. Stockpile some cash\nMarket crashes tend to spell opportunity, and so it's important to have cash at the ready for when stocks go on sale. While your first priority should be to shore up your emergency fund, if you're also able to divert some extra cash to your brokerage account, you'll put yourself in a great position to pounce while stocks are temporarily discounted.\nEven if you're a seasoned investor who follows the market closely, you probably won't be able to predict exactly when the stock market will crash next. While a May crash is certainly possible, it's also certainly not a given. But rather than spin your wheels trying to determine when that crash is coming, you should instead focus your energy on checking off the boxes above. That way, you'll really be ready for whatever is ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":27,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":106734272,"gmtCreate":1620144345196,"gmtModify":1634207461222,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"hang on guys&nbsp;","listText":"hang on guys&nbsp;","text":"hang on guys","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/106734272","repostId":"1140575890","repostType":4,"repost":{"id":"1140575890","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620141444,"share":"https://www.laohu8.com/m/news/1140575890?lang=&edition=full","pubTime":"2021-05-04 23:17","market":"us","language":"en","title":"Yellen says interest rates may have to rise somewhat to make sure economy doesn't overheat","url":"https://stock-news.laohu8.com/highlight/detail?id=1140575890","media":"Tiger Newspress","summary":"(May 4) Treasury Secretary Janet Yellen conceded Tuesday that interest rates may have to rise to kee","content":"<p>(May 4)&nbsp;Treasury Secretary Janet Yellen conceded Tuesday that interest rates may have to rise to keep a lid on the burgeoning growth of the U.S. economy brought on by trillions in government stimulus spending.</p><p>\"It may be that interest rates will have to rise somewhat to make sure that our economy doesn't overheat,\" Yellen said during a economic seminar presented by Th Atlantic. \"Even though additional spending is relatively small to the size of the economy, it could causae some very modest increases in interest rates.\"</p><p>\"But these are investments our economy needs to be competitive and productive,\" she added.</p><p>Nasdaq fell&nbsp;over 2%&nbsp;for&nbsp;now.</p><p><img src=\"https://static.tigerbbs.com/de3525661b3a7db28a0797ab745db67b\" tg-width=\"629\" tg-height=\"479\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/ec61efef423e545861c0ca0126af9332\" tg-width=\"1866\" tg-height=\"894\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yellen says interest rates may have to rise somewhat to make sure economy doesn't overheat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYellen says interest rates may have to rise somewhat to make sure economy doesn't overheat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-04 23:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(May 4)&nbsp;Treasury Secretary Janet Yellen conceded Tuesday that interest rates may have to rise to keep a lid on the burgeoning growth of the U.S. economy brought on by trillions in government stimulus spending.</p><p>\"It may be that interest rates will have to rise somewhat to make sure that our economy doesn't overheat,\" Yellen said during a economic seminar presented by Th Atlantic. \"Even though additional spending is relatively small to the size of the economy, it could causae some very modest increases in interest rates.\"</p><p>\"But these are investments our economy needs to be competitive and productive,\" she added.</p><p>Nasdaq fell&nbsp;over 2%&nbsp;for&nbsp;now.</p><p><img src=\"https://static.tigerbbs.com/de3525661b3a7db28a0797ab745db67b\" tg-width=\"629\" tg-height=\"479\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/ec61efef423e545861c0ca0126af9332\" tg-width=\"1866\" tg-height=\"894\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140575890","content_text":"(May 4) Treasury Secretary Janet Yellen conceded Tuesday that interest rates may have to rise to keep a lid on the burgeoning growth of the U.S. economy brought on by trillions in government stimulus spending.\"It may be that interest rates will have to rise somewhat to make sure that our economy doesn't overheat,\" Yellen said during a economic seminar presented by Th Atlantic. \"Even though additional spending is relatively small to the size of the economy, it could causae some very modest increases in interest rates.\"\"But these are investments our economy needs to be competitive and productive,\" she added.Nasdaq fell over 2% for now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":38,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897937226,"gmtCreate":1628867386165,"gmtModify":1631889829168,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Yes, we need a booster 👍","listText":"Yes, we need a booster 👍","text":"Yes, we need a booster 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/897937226","repostId":"1141206470","repostType":4,"repost":{"id":"1141206470","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628861824,"share":"https://www.laohu8.com/m/news/1141206470?lang=&edition=full","pubTime":"2021-08-13 21:37","market":"us","language":"en","title":"BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1141206470","media":"Tiger Newspress","summary":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster ","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141206470","content_text":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.\nBioNTech was up 3% and Moderna gained 3%, while Pfizer , which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.\n\nLate on Thursday, the U.S. Food and Drug Administration authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.\nPfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.\nGoing forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.","news_type":1},"isVote":1,"tweetType":1,"viewCount":197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164020494,"gmtCreate":1624161978318,"gmtModify":1634009984608,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"well noted !","listText":"well noted !","text":"well noted !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/164020494","repostId":"1183124175","repostType":4,"repost":{"id":"1183124175","pubTimestamp":1624151620,"share":"https://www.laohu8.com/m/news/1183124175?lang=&edition=full","pubTime":"2021-06-20 09:13","market":"us","language":"en","title":"Beware these risky tech stocks in your portfolio, strategist Parker warns","url":"https://stock-news.laohu8.com/highlight/detail?id=1183124175","media":"cnbc","summary":"As investors cycle back into growth stocks, one market strategist warns against certain technology names he believes are high risk.Growth stocks are shares of companies expected to grow at a faster rate than the rest of the market. However, these names are typically riskier and more volatile than the average stock.Adam Parker, former Morgan Stanley chief U.S. equity strategist and founder of Trivariate Research, said the time is right to buy growth shares, but investors should be cautious of a f","content":"<div>\n<p>As investors cycle back into growth stocks, one market strategist warns against certain technology names he believes are high risk.\nGrowth stocks are shares of companies expected to grow at a faster ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/19/tech-stocks-strategist-warns-of-risky-names.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beware these risky tech stocks in your portfolio, strategist Parker warns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeware these risky tech stocks in your portfolio, strategist Parker warns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-20 09:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/19/tech-stocks-strategist-warns-of-risky-names.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As investors cycle back into growth stocks, one market strategist warns against certain technology names he believes are high risk.\nGrowth stocks are shares of companies expected to grow at a faster ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/19/tech-stocks-strategist-warns-of-risky-names.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","NVDA":"英伟达","SQ":"Block","MCHP":"微芯科技","AAPL":"苹果"},"source_url":"https://www.cnbc.com/2021/06/19/tech-stocks-strategist-warns-of-risky-names.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1183124175","content_text":"As investors cycle back into growth stocks, one market strategist warns against certain technology names he believes are high risk.\nGrowth stocks are shares of companies expected to grow at a faster rate than the rest of the market. However, these names are typically riskier and more volatile than the average stock.\nAdam Parker, former Morgan Stanley chief U.S. equity strategist and founder of Trivariate Research, said the time is right to buy growth shares, but investors should be cautious of a few.\n“We think that portfolio managers should be buying growth stocks again, focusing on positive free cash flow and margin expansion, not earnings-based valuation,” Parker said in a note released Wednesday.\nTrivariate Research used a number of criteria to identify risky stocks, including low or negative correlation to inflation, high correlation to the economic reopening and high levels of company insiders selling their shares. The research firm then identified the eight riskiest names based on those measures.\n“Our view is that these are among the riskiest stocks to own today, so investors who own these names should have disproportionate upside to their base cases to compensate them for these risks,” Parker said.\nTake a look at five of the riskiest technology stocks, according to Trivariate.\nRISKIEST TECH STOCKS, ACCORDING TO TRIVARIATE\n\n\n\nTICKER\nCOMPANY\nPRICE\n%CHANGE\n\n\n\n\nMCHP\nMicrochip Technology Inc\n145.62\n-3.0686\n\n\nTWLO\nTwilio Inc\n367.61\n1.84\n\n\nSQ\nSquare Inc\n237.05\n0.39\n\n\nNVDA\nNVIDIA Corp\n745.55\n-0.0992\n\n\nAAPL\nApple Inc\n130.46\n-1.0092\n\n\n\nApple is on Trivariate’s list of riskiest stocks. The research firm identifies Apple as one of the stocks with the most negative correlation to inflation. Trivariate predicts that if bond yields rise or if fears of inflation continue, shares of Apple will underperform the market.\nNvidiaalso makes the list of risky tech stocks. Trivariate found the semiconductor stock has one of the most asymmetric beta — meaning the stock is consistently more volatile than the broader market during a market pullback compared with typical times.\nTrivariate also named payments companySquare, cloud communications platformTwilioand semiconductor manufacturerMicrochip Technologyamong the riskiest technology stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":46,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":876274245,"gmtCreate":1637327616774,"gmtModify":1637327616950,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876274245","repostId":"1138047553","repostType":4,"repost":{"id":"1138047553","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1},"isVote":1,"tweetType":1,"viewCount":712,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":895798931,"gmtCreate":1628771569923,"gmtModify":1631889829170,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"This is good news 👍","listText":"This is good news 👍","text":"This is good news 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/895798931","repostId":"1119893366","repostType":4,"repost":{"id":"1119893366","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628770120,"share":"https://www.laohu8.com/m/news/1119893366?lang=&edition=full","pubTime":"2021-08-12 20:08","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1119893366","media":"Tiger Newspress","summary":"Futures tracking the Dow hit a record high on Thursday ahead of earnings reports from companies incl","content":"<p>Futures tracking the Dow hit a record high on Thursday ahead of earnings reports from companies including Walt Disney and data expected to show a jobs market recovery was on track.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were up 35 points, or 0.1%, S&amp;P 500 E-minis were up 2 points, or 0.05% and Nasdaq 100 E-minis were up 8.5 points, or 0.06%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f35f9eb8d6574ed6eb40236f67b99935\" tg-width=\"579\" tg-height=\"200\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>Rate-sensitive lenders JPMorgan Chase &amp; Co, Wells Fargo &amp; Co, Bank of America Corp and Goldman Sachs Group Inc edged higher before the opening bell.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> – The software platform company matched Wall Street forecasts with adjusted quarterly earnings of 4 cents per share and revenue beating analyst forecasts. Sales rose 49% from a year ago, and the stock rallied 5.7% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/CYBR\">CyberArk</a> – The cybersecurity company earned an adjusted 1 cent per share for its latest quarter, compared with a consensus estimate of 2 cents, while revenue came in above estimates with subscription revenue more than doubling from a year ago. CyberArk shares slid 4.9% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/UTZ\">Utz Brands, Inc.</a> – The snack maker’s stock fell 4.5% in the premarket after it missed estimates by 2 cents with adjusted quarterly earnings of 13 cents per share, although revenue did beat Wall Street forecasts. Utz expects continued strong demand for its products, but also expects costs to remain elevated for the remainder of the year.</p>\n<p><a href=\"https://laohu8.com/S/EBAY\">eBay</a> – eBay beat estimates by 4 cents with adjusted quarterly earnings of 99 cents per share. However, it reported a decline in active buyers and is forecasting lower than expected revenue for the current quarter as overall e-commerce trends soften. eBay fell 1.5% in premarket action.</p>\n<p><a href=\"https://laohu8.com/S/BMBL\">Bumble Inc.</a> – Bumble lost 6 cents per share for its latest quarter, compared with consensus estimates for a 1 cent per-share profit. However, the dating service operator’s revenue topped forecasts as its paying user numbers jumped 20% from a year earlier, and it issued upbeat current-quarter revenue guidance. Bumble gained 1.7% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/SONO\">Sonos Inc</a> – Sonos surged 11.6% in premarket trading after it reported a surprise profit of 12 cents per share, with analysts having expected a quarterly loss of 17 cents per share. The maker of home audio equipment also issued strong current-quarter and full-year sales guidance.</p>\n<p><a href=\"https://laohu8.com/S/OPEN\">Opendoor Technologies Inc</a> – Opendoor soared 19.5% in premarket action after reporting it lost 24 cents per share for its latest quarter, 10 cents less than analysts had been projecting. The home buying and selling company also reported better-than-expected revenue, in addition to issuing an upbeat current-quarter sales forecast.</p>\n<p><a href=\"https://laohu8.com/S/RIDE\">Lordstown Motors Corp.</a> – Lordstown Motors is seeing its shares rally in the premarket after saying it was on track to begin limited production of its Endurance electric pickup truck by the end of September. Lordstown gained 1.6% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/DASH\">DoorDash, Inc.</a> – DoorDash held talks over the past two months to buy grocery delivery service Instacart, according to people familiar with the matter who spoke to The Information. The news website said the talks have fallen apart in recent weeks amid concerns that such a deal would have a difficult time winning regulatory approval. DoorDash rose 2.3% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/HIMS\">Hims &amp; Hers Health Inc.</a> – Hims &amp; Hers lost 3 cents per share for its second quarter, smaller than the 9 cents loss that Wall Street had been anticipating. The telehealth platform operator also reported better-than-expected revenue. The stock leaped 11% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/RXT\">Rackspace Technology</a> – Rackspace beat estimates by 2 cents with an adjusted quarterly profit of 24 cents per share, and the cloud computing company’s revenue also topped forecasts. However, Rackspace also gave weaker-than-expected current-quarter guidance, with the company saying it is in a “transient phase” as it phases out older business segments. Shares slumped 9.3% in premarket action.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Futures tracking the Dow hit a record high on Thursday ahead of earnings reports from companies including Walt Disney and data expected to show a jobs market recovery was on track.</p>\n<p>At 8:05 a.m. ET, Dow E-minis were up 35 points, or 0.1%, S&amp;P 500 E-minis were up 2 points, or 0.05% and Nasdaq 100 E-minis were up 8.5 points, or 0.06%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f35f9eb8d6574ed6eb40236f67b99935\" tg-width=\"579\" tg-height=\"200\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p>\n<p>Rate-sensitive lenders JPMorgan Chase &amp; Co, Wells Fargo &amp; Co, Bank of America Corp and Goldman Sachs Group Inc edged higher before the opening bell.</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> – The software platform company matched Wall Street forecasts with adjusted quarterly earnings of 4 cents per share and revenue beating analyst forecasts. Sales rose 49% from a year ago, and the stock rallied 5.7% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/CYBR\">CyberArk</a> – The cybersecurity company earned an adjusted 1 cent per share for its latest quarter, compared with a consensus estimate of 2 cents, while revenue came in above estimates with subscription revenue more than doubling from a year ago. CyberArk shares slid 4.9% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/UTZ\">Utz Brands, Inc.</a> – The snack maker’s stock fell 4.5% in the premarket after it missed estimates by 2 cents with adjusted quarterly earnings of 13 cents per share, although revenue did beat Wall Street forecasts. Utz expects continued strong demand for its products, but also expects costs to remain elevated for the remainder of the year.</p>\n<p><a href=\"https://laohu8.com/S/EBAY\">eBay</a> – eBay beat estimates by 4 cents with adjusted quarterly earnings of 99 cents per share. However, it reported a decline in active buyers and is forecasting lower than expected revenue for the current quarter as overall e-commerce trends soften. eBay fell 1.5% in premarket action.</p>\n<p><a href=\"https://laohu8.com/S/BMBL\">Bumble Inc.</a> – Bumble lost 6 cents per share for its latest quarter, compared with consensus estimates for a 1 cent per-share profit. However, the dating service operator’s revenue topped forecasts as its paying user numbers jumped 20% from a year earlier, and it issued upbeat current-quarter revenue guidance. Bumble gained 1.7% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/SONO\">Sonos Inc</a> – Sonos surged 11.6% in premarket trading after it reported a surprise profit of 12 cents per share, with analysts having expected a quarterly loss of 17 cents per share. The maker of home audio equipment also issued strong current-quarter and full-year sales guidance.</p>\n<p><a href=\"https://laohu8.com/S/OPEN\">Opendoor Technologies Inc</a> – Opendoor soared 19.5% in premarket action after reporting it lost 24 cents per share for its latest quarter, 10 cents less than analysts had been projecting. The home buying and selling company also reported better-than-expected revenue, in addition to issuing an upbeat current-quarter sales forecast.</p>\n<p><a href=\"https://laohu8.com/S/RIDE\">Lordstown Motors Corp.</a> – Lordstown Motors is seeing its shares rally in the premarket after saying it was on track to begin limited production of its Endurance electric pickup truck by the end of September. Lordstown gained 1.6% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/DASH\">DoorDash, Inc.</a> – DoorDash held talks over the past two months to buy grocery delivery service Instacart, according to people familiar with the matter who spoke to The Information. The news website said the talks have fallen apart in recent weeks amid concerns that such a deal would have a difficult time winning regulatory approval. DoorDash rose 2.3% in premarket trading.</p>\n<p><a href=\"https://laohu8.com/S/HIMS\">Hims &amp; Hers Health Inc.</a> – Hims &amp; Hers lost 3 cents per share for its second quarter, smaller than the 9 cents loss that Wall Street had been anticipating. The telehealth platform operator also reported better-than-expected revenue. The stock leaped 11% in the premarket.</p>\n<p><a href=\"https://laohu8.com/S/RXT\">Rackspace Technology</a> – Rackspace beat estimates by 2 cents with an adjusted quarterly profit of 24 cents per share, and the cloud computing company’s revenue also topped forecasts. However, Rackspace also gave weaker-than-expected current-quarter guidance, with the company saying it is in a “transient phase” as it phases out older business segments. Shares slumped 9.3% in premarket action.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119893366","content_text":"Futures tracking the Dow hit a record high on Thursday ahead of earnings reports from companies including Walt Disney and data expected to show a jobs market recovery was on track.\nAt 8:05 a.m. ET, Dow E-minis were up 35 points, or 0.1%, S&P 500 E-minis were up 2 points, or 0.05% and Nasdaq 100 E-minis were up 8.5 points, or 0.06%.\n*Source From Tiger Trade, EST 08:05\nRate-sensitive lenders JPMorgan Chase & Co, Wells Fargo & Co, Bank of America Corp and Goldman Sachs Group Inc edged higher before the opening bell.\nStocks making the biggest moves in the premarket:\nPalantir Technologies Inc. – The software platform company matched Wall Street forecasts with adjusted quarterly earnings of 4 cents per share and revenue beating analyst forecasts. Sales rose 49% from a year ago, and the stock rallied 5.7% in the premarket.\nCyberArk – The cybersecurity company earned an adjusted 1 cent per share for its latest quarter, compared with a consensus estimate of 2 cents, while revenue came in above estimates with subscription revenue more than doubling from a year ago. CyberArk shares slid 4.9% in premarket trading.\nUtz Brands, Inc. – The snack maker’s stock fell 4.5% in the premarket after it missed estimates by 2 cents with adjusted quarterly earnings of 13 cents per share, although revenue did beat Wall Street forecasts. Utz expects continued strong demand for its products, but also expects costs to remain elevated for the remainder of the year.\neBay – eBay beat estimates by 4 cents with adjusted quarterly earnings of 99 cents per share. However, it reported a decline in active buyers and is forecasting lower than expected revenue for the current quarter as overall e-commerce trends soften. eBay fell 1.5% in premarket action.\nBumble Inc. – Bumble lost 6 cents per share for its latest quarter, compared with consensus estimates for a 1 cent per-share profit. However, the dating service operator’s revenue topped forecasts as its paying user numbers jumped 20% from a year earlier, and it issued upbeat current-quarter revenue guidance. Bumble gained 1.7% in the premarket.\nSonos Inc – Sonos surged 11.6% in premarket trading after it reported a surprise profit of 12 cents per share, with analysts having expected a quarterly loss of 17 cents per share. The maker of home audio equipment also issued strong current-quarter and full-year sales guidance.\nOpendoor Technologies Inc – Opendoor soared 19.5% in premarket action after reporting it lost 24 cents per share for its latest quarter, 10 cents less than analysts had been projecting. The home buying and selling company also reported better-than-expected revenue, in addition to issuing an upbeat current-quarter sales forecast.\nLordstown Motors Corp. – Lordstown Motors is seeing its shares rally in the premarket after saying it was on track to begin limited production of its Endurance electric pickup truck by the end of September. Lordstown gained 1.6% in the premarket.\nDoorDash, Inc. – DoorDash held talks over the past two months to buy grocery delivery service Instacart, according to people familiar with the matter who spoke to The Information. The news website said the talks have fallen apart in recent weeks amid concerns that such a deal would have a difficult time winning regulatory approval. DoorDash rose 2.3% in premarket trading.\nHims & Hers Health Inc. – Hims & Hers lost 3 cents per share for its second quarter, smaller than the 9 cents loss that Wall Street had been anticipating. The telehealth platform operator also reported better-than-expected revenue. The stock leaped 11% in the premarket.\nRackspace Technology – Rackspace beat estimates by 2 cents with an adjusted quarterly profit of 24 cents per share, and the cloud computing company’s revenue also topped forecasts. However, Rackspace also gave weaker-than-expected current-quarter guidance, with the company saying it is in a “transient phase” as it phases out older business segments. Shares slumped 9.3% in premarket action.","news_type":1},"isVote":1,"tweetType":1,"viewCount":6,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125594949,"gmtCreate":1624679106181,"gmtModify":1633949671442,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Going good 👍&nbsp;","listText":"Going good 👍&nbsp;","text":"Going good 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/125594949","repostId":"1100072036","repostType":4,"repost":{"id":"1100072036","pubTimestamp":1624669285,"share":"https://www.laohu8.com/m/news/1100072036?lang=&edition=full","pubTime":"2021-06-26 09:01","market":"us","language":"en","title":"Tesla Stock Has Been on Fire This Week. Here Are 4 Reasons.","url":"https://stock-news.laohu8.com/highlight/detail?id=1100072036","media":"Barrons","summary":"Stock in electric-vehicle pioneer Tesla is on fire for seemingly no reason.There haven’t been any big,splashy upgrades that can explain the recent run. Shares have jumped almost 8% for the week and are on pace for their best week since April.Investors, rightly so, are wondering what’s going on. We found four reasons, outlined below.Many electric-vehicle stocks have been on a winning streak lately, beyond just Tesla. Coming into the week, shares of Chinese EV maker NIO were up 17% for the month.X","content":"<p>Stock in electric-vehicle pioneer&nbsp;Tesla&nbsp;is&nbsp;on fire&nbsp;for seemingly no reason.</p>\n<p>There haven’t been any big,splashy&nbsp;upgrades that can explain the recent run. Shares have jumped almost 8% for the week and are on pace for their best week since April.</p>\n<p>Investors, rightly so, are wondering what’s going on. We found four reasons, outlined below.</p>\n<p><b>Taking Cues From China</b></p>\n<p>Many electric-vehicle stocks have been on a winning streak lately, beyond just Tesla. Coming into the week, shares of Chinese EV maker&nbsp;NIO(NIO) were up 17% for the month.XPeng(XPEV) and&nbsp;Li Auto(LI) had gained 31% and 36%, respectively.</p>\n<p>Tesla, on the other hand, was down for the month of June coming into this week. But China is the world’s largest market for EVs, so when things are going well there, it bodes well for Tesla. It looks like some of the Chinese EV maker stocks’ shine has finally rubbed off on Tesla.</p>\n<p><b>Delivery Optimism</b></p>\n<p>The second reason is about second-quarter deliveries, after&nbsp;perceived weakness&nbsp;in Chinese delivery numbers. More recently, however, several&nbsp;reports&nbsp;have been popping up about Tesla working hard to deliver vehicles into the end of this month.</p>\n<p>“After a disaster start to the quarter for Tesla in China, the Street is reading the tea leaves as bullish for the month of June with momentum into [the second half],” Wedbush analyst&nbsp;Dan Ivestells&nbsp;Barron’s. He believes 900,000 deliveries is still possible for 2021. Wall Street is modeling about 825,000. Tesla delivered about 500,000 cars in 2020.</p>\n<p><b>Green Tidal Wave</b></p>\n<p>Ives has also written about a “green tidal wave” coming from the White House. President Joe Biden wants part of any infrastructure bill to include purchase incentives for EVs as well as charging infrastructure. A bill isn’t ready, but&nbsp;progress&nbsp;was made in Washington this week.</p>\n<p><b>Musk Tweeting, Again</b></p>\n<p>No search for the reason behind moves in Tesla stock would be complete without looking at CEO Elon Musk ‘s&nbsp;Twitter (TWTR) feed. He tweeted Friday that the updated full self-driving, or FSD, software and subscription pricing could roll out in as soon as a week.</p>\n<p>Tesla plans to offer its highest level of&nbsp;driver assistance, called full self-driving or FSD, on a subscription basis. It’s a new era for car companies, which don’t typically get to realize recurring revenue like software providers. Bulls have been waiting quite some time for the FSD subscription to arrive.</p>\n<p><b>What’s Next</b></p>\n<p>Next up for Tesla investors, after any FSD release, will be second-quarter delivery numbers and then earnings. Those data points come in July.</p>\n<p>Year to date, Tesla stock is still down about 4.8%, trailing behind comparable gains of the&nbsp;S&amp;P 500&nbsp;and&nbsp;Dow Jones Industrial Average.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock Has Been on Fire This Week. Here Are 4 Reasons.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock Has Been on Fire This Week. Here Are 4 Reasons.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-26 09:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-stock-gains-ev-elon-musk-51624638974?mod=hp_DAY_0><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stock in electric-vehicle pioneer Tesla is on fire for seemingly no reason.\nThere haven’t been any big,splashy upgrades that can explain the recent run. Shares have jumped almost 8% for the week and ...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-stock-gains-ev-elon-musk-51624638974?mod=hp_DAY_0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-stock-gains-ev-elon-musk-51624638974?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100072036","content_text":"Stock in electric-vehicle pioneer Tesla is on fire for seemingly no reason.\nThere haven’t been any big,splashy upgrades that can explain the recent run. Shares have jumped almost 8% for the week and are on pace for their best week since April.\nInvestors, rightly so, are wondering what’s going on. We found four reasons, outlined below.\nTaking Cues From China\nMany electric-vehicle stocks have been on a winning streak lately, beyond just Tesla. Coming into the week, shares of Chinese EV maker NIO(NIO) were up 17% for the month.XPeng(XPEV) and Li Auto(LI) had gained 31% and 36%, respectively.\nTesla, on the other hand, was down for the month of June coming into this week. But China is the world’s largest market for EVs, so when things are going well there, it bodes well for Tesla. It looks like some of the Chinese EV maker stocks’ shine has finally rubbed off on Tesla.\nDelivery Optimism\nThe second reason is about second-quarter deliveries, after perceived weakness in Chinese delivery numbers. More recently, however, several reports have been popping up about Tesla working hard to deliver vehicles into the end of this month.\n“After a disaster start to the quarter for Tesla in China, the Street is reading the tea leaves as bullish for the month of June with momentum into [the second half],” Wedbush analyst Dan Ivestells Barron’s. He believes 900,000 deliveries is still possible for 2021. Wall Street is modeling about 825,000. Tesla delivered about 500,000 cars in 2020.\nGreen Tidal Wave\nIves has also written about a “green tidal wave” coming from the White House. President Joe Biden wants part of any infrastructure bill to include purchase incentives for EVs as well as charging infrastructure. A bill isn’t ready, but progress was made in Washington this week.\nMusk Tweeting, Again\nNo search for the reason behind moves in Tesla stock would be complete without looking at CEO Elon Musk ‘s Twitter (TWTR) feed. He tweeted Friday that the updated full self-driving, or FSD, software and subscription pricing could roll out in as soon as a week.\nTesla plans to offer its highest level of driver assistance, called full self-driving or FSD, on a subscription basis. It’s a new era for car companies, which don’t typically get to realize recurring revenue like software providers. Bulls have been waiting quite some time for the FSD subscription to arrive.\nWhat’s Next\nNext up for Tesla investors, after any FSD release, will be second-quarter delivery numbers and then earnings. Those data points come in July.\nYear to date, Tesla stock is still down about 4.8%, trailing behind comparable gains of the S&P 500 and Dow Jones Industrial Average.","news_type":1},"isVote":1,"tweetType":1,"viewCount":45,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":876567162,"gmtCreate":1637333054328,"gmtModify":1637333058832,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876567162","repostId":"1129693973","repostType":2,"repost":{"id":"1129693973","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637332940,"share":"https://www.laohu8.com/m/news/1129693973?lang=&edition=full","pubTime":"2021-11-19 22:42","market":"us","language":"en","title":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1129693973","media":"Tiger Newspress","summary":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US)","content":"<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p>\n<p>The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p>\n<p>Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p>\n<p>The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p>\n<p>Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129693973","content_text":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.\nThe report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"\nMoreover，Moderna, Inc. today announced that the U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":386,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853879081,"gmtCreate":1634793211465,"gmtModify":1634793211614,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853879081","repostId":"1115514997","repostType":4,"repost":{"id":"1115514997","pubTimestamp":1634771335,"share":"https://www.laohu8.com/m/news/1115514997?lang=&edition=full","pubTime":"2021-10-21 07:08","market":"us","language":"en","title":"FDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing","url":"https://stock-news.laohu8.com/highlight/detail?id=1115514997","media":"Bloomberg","summary":"Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be gi","content":"<ul>\n <li>Actions mean extra doses now allowed for all three U.S. shots</li>\n <li>Agency allows different shots to be given to bolster immunity</li>\n</ul>\n<p>The U.S. Food and Drug Administration cleared a path for millions more Americans to receive Covid-19 vaccine booster shots, as the nation looks to bolster its defenses and prevent another virus surge.</p>\n<p>The agency said in a&nbsp;statement&nbsp;on Wednesday that&nbsp;Moderna Inc.&nbsp;vaccine recipients 65 and over can receive a third shot, as can adults 18 and up who are at high risk of severe Covid or with frequent institutional or occupational exposure to the virus that causes the disease.</p>\n<p>Additionally, all J&amp;J recipients 18 and older are eligible for a booster shot at least two months after receiving their first dose.</p>\n<p>The agency also allowed each of the available Covid vaccines to be used as a booster dose for eligible individuals following completion of a primary vaccination with a different vaccine.</p>\n<p>The moves will mean the U.S. has a bigger toolkit to try to limit a potential winter virus rebound. The summer’s delta-variant fueled spike in infections helped increase urgency to make boosters available, and health officials across the U.S. are eager to forestall a rebound in cases that could cripple hospitals and disrupt work and school this winter.</p>\n<p>FDA officials indicated they would also move quickly to expand eligibility for booster shots as more data become available or if breakthrough cases start to rise in younger adults.</p>\n<p>“We will not hesitate to drop this age range as we see that that benefit clearly outweighs the risk,” said Peter Marks, the head of the agency’s Center for Biologics Evaluation and Research, during a media briefing following the announcement.</p>\n<p>The clearances came after a panel of expert advisers to the FDA unanimously backed the Moderna and J&amp;J booster regimens in two days of meetings last week. Regulators have now signed off on boosters for all three coronavirus vaccines available in the U.S.</p>\n<p>Last month, the FDA said people 65 and over and others who are at heightened risk of severe Covid were eligible for a booster dose of the vaccine developed by&nbsp;Pfizer Inc.&nbsp;and&nbsp;BioNTech SE.</p>\n<p>Moderna shares climbed 1% in after-hours trading in New York, while J&amp;J shares gained 0.4% and Pfizer shares rose 0.2%. U.S.-traded shares of Germany-based BioNTech gained 0.9%.</p>\n<p><b>Smaller Dose</b></p>\n<p>The Moderna booster shot authorized by the FDA is half the dose that is given in the initial two-shot series, and it should be given at least six months after the initial inoculation, regulators said.</p>\n<p>The FDA said that a single booster dose of the Pfizer vaccine may be given at least 6 months after completing the primary series to people 18 to 64 with frequent institutional or occupational exposure to the coronavirus.</p>\n<p>In permitting mixing and matching, the FDA is allowing J&amp;J vaccine recipients to receive an additional dose of any cleared vaccine after two months. Likewise, recipients of Moderna and Pfizer who are eligible for a booster would receive their booster, including J&amp;J’s shot, at least six months after their initial immunization regimen.</p>\n<p>Marks said during the call with reporters that different combinations produce different antibody levels in the short term, but it isn’t clear what that means in terms of actual long-term protection.</p>\n<p>Seen as a convenient, effective alternative to two-shot messenger RNA vaccines, J&amp;J’s single-shot immunization has seen far less use in the U.S., in part because it isn’t as effective. The drugmaker has also experienced manufacturing problems that limited the shot’s distribution.</p>\n<p>The decision to allow mixing will create greater flexibility and is beneficial to global public health, Paul Stoffels, J&amp;J’s chief scientific officer, said in a statement.</p>\n<p>Before the Moderna and J&amp;J booster shots can be administered, the Centers for Disease Control and Prevention’s Advisory Panel on Immunization Practices will make further recommendations about who should receive them. The panel is scheduled to discuss boosters on Thursday.</p>\n<p>The next big milestone for the U.S. immunization effort looms next week, when the FDA advisory panel is expected to weigh Pfizer’s proposed Covid vaccine for children ages 5 to 11. If authorized, it could begin to roll out to pediatricians’ offices and drugstores as soon as next month.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Clears Moderna, J&J Boosters and Backs Vaccine Mixing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-21 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be given to bolster immunity\n\nThe U.S. Food and Drug Administration cleared a path for millions more ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","MRK":"默沙东","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","JNJ":"强生","BNTX":"BioNTech SE"},"source_url":"https://www.bloomberg.com/news/articles/2021-10-20/fda-clears-moderna-j-j-covid-boosters-and-backs-vaccine-mixing","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115514997","content_text":"Actions mean extra doses now allowed for all three U.S. shots\nAgency allows different shots to be given to bolster immunity\n\nThe U.S. Food and Drug Administration cleared a path for millions more Americans to receive Covid-19 vaccine booster shots, as the nation looks to bolster its defenses and prevent another virus surge.\nThe agency said in a statement on Wednesday that Moderna Inc. vaccine recipients 65 and over can receive a third shot, as can adults 18 and up who are at high risk of severe Covid or with frequent institutional or occupational exposure to the virus that causes the disease.\nAdditionally, all J&J recipients 18 and older are eligible for a booster shot at least two months after receiving their first dose.\nThe agency also allowed each of the available Covid vaccines to be used as a booster dose for eligible individuals following completion of a primary vaccination with a different vaccine.\nThe moves will mean the U.S. has a bigger toolkit to try to limit a potential winter virus rebound. The summer’s delta-variant fueled spike in infections helped increase urgency to make boosters available, and health officials across the U.S. are eager to forestall a rebound in cases that could cripple hospitals and disrupt work and school this winter.\nFDA officials indicated they would also move quickly to expand eligibility for booster shots as more data become available or if breakthrough cases start to rise in younger adults.\n“We will not hesitate to drop this age range as we see that that benefit clearly outweighs the risk,” said Peter Marks, the head of the agency’s Center for Biologics Evaluation and Research, during a media briefing following the announcement.\nThe clearances came after a panel of expert advisers to the FDA unanimously backed the Moderna and J&J booster regimens in two days of meetings last week. Regulators have now signed off on boosters for all three coronavirus vaccines available in the U.S.\nLast month, the FDA said people 65 and over and others who are at heightened risk of severe Covid were eligible for a booster dose of the vaccine developed by Pfizer Inc. and BioNTech SE.\nModerna shares climbed 1% in after-hours trading in New York, while J&J shares gained 0.4% and Pfizer shares rose 0.2%. U.S.-traded shares of Germany-based BioNTech gained 0.9%.\nSmaller Dose\nThe Moderna booster shot authorized by the FDA is half the dose that is given in the initial two-shot series, and it should be given at least six months after the initial inoculation, regulators said.\nThe FDA said that a single booster dose of the Pfizer vaccine may be given at least 6 months after completing the primary series to people 18 to 64 with frequent institutional or occupational exposure to the coronavirus.\nIn permitting mixing and matching, the FDA is allowing J&J vaccine recipients to receive an additional dose of any cleared vaccine after two months. Likewise, recipients of Moderna and Pfizer who are eligible for a booster would receive their booster, including J&J’s shot, at least six months after their initial immunization regimen.\nMarks said during the call with reporters that different combinations produce different antibody levels in the short term, but it isn’t clear what that means in terms of actual long-term protection.\nSeen as a convenient, effective alternative to two-shot messenger RNA vaccines, J&J’s single-shot immunization has seen far less use in the U.S., in part because it isn’t as effective. The drugmaker has also experienced manufacturing problems that limited the shot’s distribution.\nThe decision to allow mixing will create greater flexibility and is beneficial to global public health, Paul Stoffels, J&J’s chief scientific officer, said in a statement.\nBefore the Moderna and J&J booster shots can be administered, the Centers for Disease Control and Prevention’s Advisory Panel on Immunization Practices will make further recommendations about who should receive them. The panel is scheduled to discuss boosters on Thursday.\nThe next big milestone for the U.S. immunization effort looms next week, when the FDA advisory panel is expected to weigh Pfizer’s proposed Covid vaccine for children ages 5 to 11. If authorized, it could begin to roll out to pediatricians’ offices and drugstores as soon as next month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":544,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824668787,"gmtCreate":1634308679503,"gmtModify":1634308679653,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/824668787","repostId":"2175143354","repostType":2,"isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":835846530,"gmtCreate":1629706882520,"gmtModify":1631884085491,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Well done Pfizer 👍","listText":"Well done Pfizer 👍","text":"Well done Pfizer 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835846530","repostId":"1104804215","repostType":4,"repost":{"id":"1104804215","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629706373,"share":"https://www.laohu8.com/m/news/1104804215?lang=&edition=full","pubTime":"2021-08-23 16:12","market":"us","language":"en","title":"Pfizer and BioNTech SE shares surged in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104804215","media":"Tiger Newspress","summary":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval","content":"<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p>\n<p><img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p>\n<p>The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p>\n<p>Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p>\n<p>An F.D.A. spokeswoman declined to comment.</p>\n<p>The agency had recently set an unofficial deadline for approval of around Labor Day.</p>\n<p>The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p>\n<p>Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p>\n<p>Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p>\n<p>The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p>\n<p>Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech SE shares surged in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech SE shares surged in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-23 16:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p>\n<p><img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p>\n<p>The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p>\n<p>Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p>\n<p>An F.D.A. spokeswoman declined to comment.</p>\n<p>The agency had recently set an unofficial deadline for approval of around Labor Day.</p>\n<p>The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p>\n<p>Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p>\n<p>Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p>\n<p>The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p>\n<p>Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104804215","content_text":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.\n\nThe Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.\nRegulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.\nAn F.D.A. spokeswoman declined to comment.\nThe agency had recently set an unofficial deadline for approval of around Labor Day.\nThe approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.\nSome universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month said it planned to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.\nOnce it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.\nThe F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.\nRegulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.","news_type":1},"isVote":1,"tweetType":1,"viewCount":63,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893833716,"gmtCreate":1628253506135,"gmtModify":1631889829174,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/893833716","repostId":"1195593033","repostType":4,"isVote":1,"tweetType":1,"viewCount":64,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804966742,"gmtCreate":1627916792786,"gmtModify":1633755274197,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"I am watching 😳","listText":"I am watching 😳","text":"I am watching 😳","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804966742","repostId":"1196763976","repostType":4,"repost":{"id":"1196763976","pubTimestamp":1627903466,"share":"https://www.laohu8.com/m/news/1196763976?lang=&edition=full","pubTime":"2021-08-02 19:24","market":"us","language":"en","title":"When Will Stocks Drop? Watch Profit Margins (and Get Nervous)","url":"https://stock-news.laohu8.com/highlight/detail?id=1196763976","media":"Bloomberg","summary":"The evidence is mounting that companies are having a harder time passing off cost increases to their","content":"<blockquote>\n The evidence is mounting that companies are having a harder time passing off cost&nbsp;increases to their customers.\n</blockquote>\n<p>Want to know where the S&amp;P 500 Index may be headed after reaching another record high? Take a look at profit margins.</p>\n<p>Operating margin forecasts are a strong leading indicator of stock prices. A decline in such outlooks preceded routs in the S&amp;P 500 in 2011, 2015, 2018 and 2020. What’s concerning now is that analysts have stopped raising their forecasts, and if they begin to lower them, it's likely to lead to a dip in the broader market again. And it’s not like there’s a lot of room for further improvement in margins, defined as earnings before interest and taxes divided by sales. The consensus among analysts is that they will expand to 16.7% over the next 12 months, topping the previous record of 16.4% set in 2018.</p>\n<p>The relationship between S&amp;P 500 profitability and inflation indicators is murky at best, but recent spikes in the producer price index and a smaller increase in the consumer price index is enough to raise a caution flag for equity margin expansion potential for the next few quarters. At its peak in April, the PPI rose 9.5% from a year earlier, almost 3 standard deviations above its average over the past 30 years. (It rose 9.4% in June.) From 2010 to 2019, the median estimate of where operating margins would be 12 months into the future for S&amp;P 500 members were negatively correlated to changes in PPI. The current coefficient of minus 0.22 suggests gains in corporate profitability are likely to stall or even fall as producer prices continue to rise.</p>\n<p><b>Watch Those Margins</b></p>\n<p>Past dips in forecasted profit margins have lined up with pull-backs in equities.</p>\n<p><img src=\"https://static.tigerbbs.com/2dbda2c0b9394d518fdc8af7d693c8f3\" tg-width=\"644\" tg-height=\"283\" width=\"100%\" height=\"auto\">The difference between the PPI and CPI suggests companies are unable to pass cost increases on to consumers. The spread between the two fell to a record low of minus 5.3 percentage points in April, and is still strongly inverted at minus 4.1 percentage points. Over the last 30 years, the operating margin for the S&amp;P 500 narrowed 6.5 percentage points on average one year after the gap fell below minus 2 percentage points. Not only that, but in the year after the spread breached minus 2 percentage points, the S&amp;P fell 2.5% on average.</p>\n<p>Analysts are getting nervous. They have cut their margin estimates for a quarter of S&amp;P 500 members in the last three months. Their stocks were down 0.63%, compared with a gain of 2.20% for the index and a 3.30% increase for companies with rising margin forecasts. Slicing the index into quintiles based on changes in operating margin shows that companies with the largest declines had a median stock-price decline of 0.5%, versus a gain of 3.9% for those with the greatest expansion in consensus estimates.</p>\n<p>Industries with the most negative margin pressures are likely to be those that investors historically consider “defensive,” such as health care, utilities and consumer staples. Large companies involved in pharmaceuticals, biotechnology and life sciences, household and personal products, and utilities have historically fared worst when producer prices outrun consumer prices, and these are where margin forecasts gave dropped the most over the last three months. Margins forecasts continue to rise for the more cyclically-oriented segments of the equity market, with media, consumer services, transportation and oil and gas industries having the largest gains.</p>\n<p><b>Winners and Losers</b></p>\n<p>Cyclically-oriented sectors are relatively immune from broad profit margin compression.</p>\n<p><img src=\"https://static.tigerbbs.com/884366efc825eccec2878fcd4b3f0912\" tg-width=\"640\" tg-height=\"533\" width=\"100%\" height=\"auto\">Though consensus expectations imply smooth sailing, companies are set up for a more challenging margin outlook as revenue growth rates likely fade, but inflation pressures remain relatively high given persistent uncertainty in the supply chain. Against this backdrop, currently selective industry margin weaknesses may start to spread to more industries, resulting in degradation of margin forecasts for the index at large. Given these estimates are a strong strong leading indicator of stock-price direction, margin trends may be a critical risk to the equity market in the months ahead.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>When Will Stocks Drop? Watch Profit Margins (and Get Nervous)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhen Will Stocks Drop? Watch Profit Margins (and Get Nervous)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 19:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The evidence is mounting that companies are having a harder time passing off cost increases to their customers.\n\nWant to know where the S&P 500 Index may be headed after reaching another record high? ...</p>\n\n<a href=\"https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.bloomberg.com/opinion/articles/2021-08-02/stock-market-margin-mayhem-looms-large-over-bull-market?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196763976","content_text":"The evidence is mounting that companies are having a harder time passing off cost increases to their customers.\n\nWant to know where the S&P 500 Index may be headed after reaching another record high? Take a look at profit margins.\nOperating margin forecasts are a strong leading indicator of stock prices. A decline in such outlooks preceded routs in the S&P 500 in 2011, 2015, 2018 and 2020. What’s concerning now is that analysts have stopped raising their forecasts, and if they begin to lower them, it's likely to lead to a dip in the broader market again. And it’s not like there’s a lot of room for further improvement in margins, defined as earnings before interest and taxes divided by sales. The consensus among analysts is that they will expand to 16.7% over the next 12 months, topping the previous record of 16.4% set in 2018.\nThe relationship between S&P 500 profitability and inflation indicators is murky at best, but recent spikes in the producer price index and a smaller increase in the consumer price index is enough to raise a caution flag for equity margin expansion potential for the next few quarters. At its peak in April, the PPI rose 9.5% from a year earlier, almost 3 standard deviations above its average over the past 30 years. (It rose 9.4% in June.) From 2010 to 2019, the median estimate of where operating margins would be 12 months into the future for S&P 500 members were negatively correlated to changes in PPI. The current coefficient of minus 0.22 suggests gains in corporate profitability are likely to stall or even fall as producer prices continue to rise.\nWatch Those Margins\nPast dips in forecasted profit margins have lined up with pull-backs in equities.\nThe difference between the PPI and CPI suggests companies are unable to pass cost increases on to consumers. The spread between the two fell to a record low of minus 5.3 percentage points in April, and is still strongly inverted at minus 4.1 percentage points. Over the last 30 years, the operating margin for the S&P 500 narrowed 6.5 percentage points on average one year after the gap fell below minus 2 percentage points. Not only that, but in the year after the spread breached minus 2 percentage points, the S&P fell 2.5% on average.\nAnalysts are getting nervous. They have cut their margin estimates for a quarter of S&P 500 members in the last three months. Their stocks were down 0.63%, compared with a gain of 2.20% for the index and a 3.30% increase for companies with rising margin forecasts. Slicing the index into quintiles based on changes in operating margin shows that companies with the largest declines had a median stock-price decline of 0.5%, versus a gain of 3.9% for those with the greatest expansion in consensus estimates.\nIndustries with the most negative margin pressures are likely to be those that investors historically consider “defensive,” such as health care, utilities and consumer staples. Large companies involved in pharmaceuticals, biotechnology and life sciences, household and personal products, and utilities have historically fared worst when producer prices outrun consumer prices, and these are where margin forecasts gave dropped the most over the last three months. Margins forecasts continue to rise for the more cyclically-oriented segments of the equity market, with media, consumer services, transportation and oil and gas industries having the largest gains.\nWinners and Losers\nCyclically-oriented sectors are relatively immune from broad profit margin compression.\nThough consensus expectations imply smooth sailing, companies are set up for a more challenging margin outlook as revenue growth rates likely fade, but inflation pressures remain relatively high given persistent uncertainty in the supply chain. Against this backdrop, currently selective industry margin weaknesses may start to spread to more industries, resulting in degradation of margin forecasts for the index at large. Given these estimates are a strong strong leading indicator of stock-price direction, margin trends may be a critical risk to the equity market in the months ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":83,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159736628,"gmtCreate":1624979415364,"gmtModify":1633946216435,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Great news 🎉","listText":"Great news 🎉","text":"Great news 🎉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159736628","repostId":"1121320099","repostType":4,"repost":{"id":"1121320099","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624978930,"share":"https://www.laohu8.com/m/news/1121320099?lang=&edition=full","pubTime":"2021-06-29 23:02","market":"us","language":"en","title":"AMD stock surged 3% in Tuesday morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1121320099","media":"Tiger Newspress","summary":"AMD stock surged 3% on AMD's planned purchase of Xilinx being approved by UK's antitrust authority.X","content":"<p>AMD stock surged 3%&nbsp;on&nbsp;AMD's planned purchase of Xilinx being&nbsp;approved by UK's antitrust authority.Xilinx&nbsp;shares&nbsp;surged&nbsp;2%.</p>\n<p><img src=\"https://static.tigerbbs.com/34ea51d2655a990239ad58f1954a71dd\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li>AMD's(NASDAQ:AMD)&nbsp;planned $35B acquisition of Xilinx(NASDAQ:XLNX)has been approved by the UK's Competition and Markets Authority.</li>\n <li>The approval was disclosed on the&nbsp;UK CMA's website.</li>\n <li>In May&nbsp;the UK's CMA said it started its inquiry into the proposed deal.</li>\n <li>Earlier this month, Xilinx gained after report that&nbsp;European antitrust reportedly has no issues&nbsp;with AMD deal. The provisional deadline for EU is June 30.</li>\n <li>The deal still is awaiting approval in China.</li>\n</ul>\n<p>In January, the mandatory waiting period required for the FTC and Department of Justice to&nbsp;investigate deals for potential antitrust issues expired.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD stock surged 3% in Tuesday morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD stock surged 3% in Tuesday morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-29 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMD stock surged 3%&nbsp;on&nbsp;AMD's planned purchase of Xilinx being&nbsp;approved by UK's antitrust authority.Xilinx&nbsp;shares&nbsp;surged&nbsp;2%.</p>\n<p><img src=\"https://static.tigerbbs.com/34ea51d2655a990239ad58f1954a71dd\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li>AMD's(NASDAQ:AMD)&nbsp;planned $35B acquisition of Xilinx(NASDAQ:XLNX)has been approved by the UK's Competition and Markets Authority.</li>\n <li>The approval was disclosed on the&nbsp;UK CMA's website.</li>\n <li>In May&nbsp;the UK's CMA said it started its inquiry into the proposed deal.</li>\n <li>Earlier this month, Xilinx gained after report that&nbsp;European antitrust reportedly has no issues&nbsp;with AMD deal. The provisional deadline for EU is June 30.</li>\n <li>The deal still is awaiting approval in China.</li>\n</ul>\n<p>In January, the mandatory waiting period required for the FTC and Department of Justice to&nbsp;investigate deals for potential antitrust issues expired.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121320099","content_text":"AMD stock surged 3% on AMD's planned purchase of Xilinx being approved by UK's antitrust authority.Xilinx shares surged 2%.\n\n\nAMD's(NASDAQ:AMD) planned $35B acquisition of Xilinx(NASDAQ:XLNX)has been approved by the UK's Competition and Markets Authority.\nThe approval was disclosed on the UK CMA's website.\nIn May the UK's CMA said it started its inquiry into the proposed deal.\nEarlier this month, Xilinx gained after report that European antitrust reportedly has no issues with AMD deal. The provisional deadline for EU is June 30.\nThe deal still is awaiting approval in China.\n\nIn January, the mandatory waiting period required for the FTC and Department of Justice to investigate deals for potential antitrust issues expired.","news_type":1},"isVote":1,"tweetType":1,"viewCount":86,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164306214,"gmtCreate":1624169508938,"gmtModify":1634009849889,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Well written 👍","listText":"Well written 👍","text":"Well written 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/164306214","repostId":"1133385197","repostType":4,"isVote":1,"tweetType":1,"viewCount":4,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835534807,"gmtCreate":1629726519709,"gmtModify":1631889829164,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"we need this 🙏","listText":"we need this 🙏","text":"we need this 🙏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/835534807","repostId":"1189910879","repostType":4,"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890960248,"gmtCreate":1628076808384,"gmtModify":1631889829186,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Great news from Pfizer 👏🏻 well done","listText":"Great news from Pfizer 👏🏻 well done","text":"Great news from Pfizer 👏🏻 well done","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/890960248","repostId":"2156103241","repostType":2,"isVote":1,"tweetType":1,"viewCount":45,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805749936,"gmtCreate":1627909553825,"gmtModify":1633755401881,"author":{"id":"3582662259235370","authorId":"3582662259235370","name":"airmanbc","avatar":"https://static.tigerbbs.com/d3bd9bef9a69c52c326c615c50baad14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582662259235370","authorIdStr":"3582662259235370"},"themes":[],"htmlText":"Looks good 👍&nbsp;","listText":"Looks good 👍&nbsp;","text":"Looks good 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/805749936","repostId":"1191057621","repostType":4,"isVote":1,"tweetType":1,"viewCount":28,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}